JPWO2006035900A1 - Coenzyme Q10-containing emulsion composition - Google Patents
Coenzyme Q10-containing emulsion composition Download PDFInfo
- Publication number
- JPWO2006035900A1 JPWO2006035900A1 JP2006537821A JP2006537821A JPWO2006035900A1 JP WO2006035900 A1 JPWO2006035900 A1 JP WO2006035900A1 JP 2006537821 A JP2006537821 A JP 2006537821A JP 2006537821 A JP2006537821 A JP 2006537821A JP WO2006035900 A1 JPWO2006035900 A1 JP WO2006035900A1
- Authority
- JP
- Japan
- Prior art keywords
- coenzyme
- weight
- lecithin
- emulsion composition
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 263
- 239000000203 mixture Substances 0.000 title claims abstract description 251
- 239000000839 emulsion Substances 0.000 title claims description 162
- 235000017471 coenzyme Q10 Nutrition 0.000 title abstract description 17
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title abstract description 8
- 229940110767 coenzyme Q10 Drugs 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 111
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000004094 surface-active agent Substances 0.000 claims abstract description 48
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 38
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 78
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 78
- 239000000787 lecithin Substances 0.000 claims description 78
- 235000010445 lecithin Nutrition 0.000 claims description 78
- 229940067606 lecithin Drugs 0.000 claims description 78
- -1 glycerol fatty acid esters Chemical class 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 71
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 64
- 229930195729 fatty acid Natural products 0.000 claims description 64
- 239000000194 fatty acid Substances 0.000 claims description 64
- 235000013305 food Nutrition 0.000 claims description 61
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 60
- 235000011187 glycerol Nutrition 0.000 claims description 53
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 46
- 230000003078 antioxidant effect Effects 0.000 claims description 36
- 239000003963 antioxidant agent Substances 0.000 claims description 34
- 235000006708 antioxidants Nutrition 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 30
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 23
- 229960002446 octanoic acid Drugs 0.000 claims description 23
- 238000010521 absorption reaction Methods 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 239000002537 cosmetic Substances 0.000 claims description 20
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 12
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 241000282412 Homo Species 0.000 claims description 9
- 239000005639 Lauric acid Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 7
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000005515 coenzyme Substances 0.000 claims description 5
- 230000003381 solubilizing effect Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 19
- 230000001804 emulsifying effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 35
- 239000000047 product Substances 0.000 description 30
- 235000013361 beverage Nutrition 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 23
- 150000003904 phospholipids Chemical class 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 235000021110 pickles Nutrition 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 238000004945 emulsification Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 235000015203 fruit juice Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- 244000299461 Theobroma cacao Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 229960004203 carnitine Drugs 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000015067 sauces Nutrition 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000011962 puddings Nutrition 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 3
- 235000013793 astaxanthin Nutrition 0.000 description 3
- 239000001168 astaxanthin Substances 0.000 description 3
- 229940022405 astaxanthin Drugs 0.000 description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- 235000010930 zeaxanthin Nutrition 0.000 description 3
- 239000001775 zeaxanthin Substances 0.000 description 3
- 229940043269 zeaxanthin Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 239000011774 beta-cryptoxanthin Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical class C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000004579 marble Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 229930188627 soysaponin Natural products 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229930185549 teaseedsaponin Natural products 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- AVZIYOYFVVSTGQ-RBWRNIRVSA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O AVZIYOYFVVSTGQ-RBWRNIRVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- VJXUJFAZXQOXMJ-UHFFFAOYSA-N D-1-O-Methyl-muco-inositol Natural products CC12C(OC)(C)OC(C)(C)C2CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 VJXUJFAZXQOXMJ-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001653 FEMA 3120 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010074063 Ischaemic enteritis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241001532059 Yucca Species 0.000 description 1
- 235000004552 Yucca aloifolia Nutrition 0.000 description 1
- 235000012044 Yucca brevifolia Nutrition 0.000 description 1
- 235000017049 Yucca glauca Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019465 surimi Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
- A23L35/10—Emulsified foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
Abstract
本発明は、コエンザイムQ10を含有する、保存安定性、水への溶解性や分散性に優れた乳化組成物を提供する。また本発明はコエンザイムQ10を含有する体内吸収性に優れた乳化組成物を提供する。本発明の乳化組成物は、コエンザイムQ10を、特定の割合の中鎖トリグリセライド、界面活性剤、及び多価アルコールを用いて特定の割合の水に乳化させることによって調製することができる。The present invention provides an emulsified composition containing coenzyme Q10 and excellent in storage stability, solubility in water and dispersibility. The present invention also provides an emulsified composition having coenzyme Q10 and excellent absorbability in the body. The emulsified composition of the present invention can be prepared by emulsifying coenzyme Q10 in a specific ratio of water using a specific ratio of medium-chain triglyceride, a surfactant, and a polyhydric alcohol.
Description
本発明は、コエンザイムQ10を含有する乳化組成物に関する。より詳細には、本発明は保存安定性に優れ、また水に対する溶解性または分散性に優れたコエンザイムQ10含有乳化組成物に関する。さらに本発明は、生体吸収性、特に経口投与による生体吸収性に優れたコエンザイムQ10含有乳化組成物に関する。The present invention relates to an emulsion composition containing Coenzyme Q 10. More particularly, the present invention is excellent in storage stability, also relates to solubility or excellent coenzyme Q 10 containing emulsion compositions dispersible in water. The invention further bioabsorbable relates excellent Coenzyme Q 10 containing emulsion composition bioabsorbable particularly by oral administration.
また本発明は、かかるコエンザイムQ10含有乳化組成物を含有する各種の製品、特にコエンザイムQ10含有乳化組成物を水に可溶化または分散させた水性液状製品に関する。さらに本発明は、コエンザイムQ10について体内吸収性を高める方法、並びに体内抗酸化能を高める方法に関する。The present invention, various products containing such coenzyme Q 10 containing emulsion composition, an aqueous liquid products in particular Coenzyme Q 10 containing emulsion composition is solubilized or dispersed in water. The present invention relates to a method of increasing the systemic absorption of the coenzyme Q 10, and to a method of increasing the body antioxidant capacity.
コエンザイムQ10は、生体内でのATP(アデノシン三リン酸)産生に欠かせない成分として真核細胞のミトコンドリアに多く存在し、生体エネルギー産生の必須成分と言われている。Coenzyme Q 10 is present more in the mitochondria of eukaryotic cells as ATP indispensable (adenosine triphosphate) production components in vivo, it is said that an essential component of biological energy production.
また、生体内で優れた抗酸化機能を発揮することが知られており、生体内で活性酸素が関与すると考えられている疾患、例えば、心筋梗塞、高血圧、狭心症、及び癌などのいわゆる生活習慣病と呼ばれる疾病に対して予防効果が期待されている。さらに、アルツハイマー、パーキンソン病、及びうつ病などの脳疾患、歯肉歯周病、並びに筋ジストロフィーなどの各種の疾病に対して予防効果があるほか、肥満防止効果や、新陳代謝促進作用による老化防止効果などがあるとされている。 In addition, it is known to exhibit an excellent antioxidant function in vivo, and so-called diseases such as myocardial infarction, hypertension, angina pectoris, and cancer, which are considered to be associated with active oxygen in vivo. It is expected to have a preventive effect on diseases called lifestyle-related diseases. Furthermore, it has preventive effects on various diseases such as brain diseases such as Alzheimer, Parkinson's disease, and depression, gingival periodontal disease, and muscular dystrophy, as well as anti-obesity effects and anti-aging effects by promoting metabolism. It is said that there is.
コエンザイムQ10の生体内での需要の一部は、体内合成によってまかなわれているが、それ以外は食物から取り入れられている。生体内合成量は加齢により低下することが知られている。また食物から得られる量はごく僅かであるので、結果的に生体内で賄われるコエンザイムQ10の総量は、加齢とともに減少することとなる。従って、体内合成量を補う目的で、現在では体外から、例えばサプリメント等として摂取することが盛んに行なわれている。Some of the demand in vivo of coenzyme Q 10 is being covered by the endogenous synthesis, otherwise are taken from food. It is known that the amount of in vivo synthesis decreases with age. Since the amount obtained from food is negligible, the total amount of coenzyme Q 10 to be eventually covered in vivo, and to decrease with age. Therefore, for the purpose of supplementing the amount of synthesis in the body, at present, it is actively taken from outside the body, for example, as a supplement.
コエンザイムQ10は油溶性の物質である。このため、現在市販されている経口投与型のコエンザイムQ10サプリメントは基本的にコエンザイムQ10の結晶粉末を油脂に分散または油脂に溶解させたものか、またはコエンザイムQ10の結晶粉末をカプセルに封入したものが大半である。しかしながら、こうした状態のものは摂取しても、体内への吸収率、とりわけ空腹時の体内有効利用率(バイオアベイラビリティー)が非常に低いことが解っている。Coenzyme Q 10 is a material of the oil-soluble. Therefore, sealed or not was present oral dosage form of coenzyme Q 10 supplements on the market are basically the crystal powder of coenzyme Q 10 is dissolved in the dispersion or fat to fat, or a crystalline powder of coenzyme Q 10 in the capsule Most of them have been done. However, even when ingested in such a state, it has been found that the absorption rate into the body, especially the effective utilization rate (bioavailability) in the fasting in the body is very low.
従来から、コエンザイムQ10等のような脂溶性成分を、水溶性の食品、医薬品または化粧品等に安定的に配合する方法として、一般的に乳化・可溶化という方法が採用されている。具体的には、食用油等の油性溶媒に脂溶性成分を溶かし、これを、界面活性剤を溶解した水性溶媒と混合して乳化・可溶化する方法を例示することができる。Conventionally, the fat-soluble components such as coenzyme Q 10, water-soluble food, as a method of blending stably pharmaceuticals or cosmetics, the method has been employed that generally emulsification and solubilization. Specifically, a method in which a fat-soluble component is dissolved in an oily solvent such as edible oil, and this is mixed with an aqueous solvent in which a surfactant is dissolved to be emulsified and solubilized can be exemplified.
脂溶性成分を乳化または可溶化して水溶性の製剤とする方法として、より具体的には、例えば、脂溶性物質を、乳化剤、多価アルコールおよび水とともに高圧処理する方法(特許文献1)、脂溶性成分(非水溶性の物質)を、ポリグリセリン脂肪酸エステルとショ糖脂肪酸エステルを用いて水または多価アルコールに可溶化、乳化または分散させる方法(特許文献2)、膜形成分子(リン脂質)を、乳化助剤と油性成分に溶解し、これを水性相に添加して乳化させる方法(特許文献3)、脂溶性成分(セラミド)を炭素数8〜10の脂肪酸とポリグリセリンのエステルと炭素数12〜18の脂肪酸とポリグリセリンのエステルを用いて水系溶媒に分散させる方法(特許文献4)、植物ステロール及び/または植物ステロール脂肪酸エステルを含む油相を、酵素処理卵黄を乳化剤として用いて水相に乳化させる方法(特許文献5)、脂溶性成分(非水溶性物質)に、ポリグリセリン脂肪酸エステル、多価アルコール及び水を混合して可溶化する方法(特許文献6)、脂溶性成分を、油相成分、多価アルコールおよび乳化剤を用いて乳化させる方法(特許文献7、8)を挙げることができる。 As a method of emulsifying or solubilizing a fat-soluble component to obtain a water-soluble preparation, more specifically, for example, a method of high-pressure treatment of a fat-soluble substance together with an emulsifier, a polyhydric alcohol and water (Patent Document 1), A method of solubilizing, emulsifying or dispersing a fat-soluble component (water-insoluble substance) in water or a polyhydric alcohol using a polyglycerin fatty acid ester and a sucrose fatty acid ester (Patent Document 2), a film-forming molecule (phospholipid) ) Is dissolved in an emulsification aid and an oil component, and this is added to an aqueous phase to emulsify (Patent Document 3), and a fat-soluble component (ceramide) is an ester of a fatty acid having 8 to 10 carbon atoms and a polyglycerol. A method of dispersing in a water-based solvent using a fatty acid having 12 to 18 carbon atoms and an ester of polyglycerin (Patent Document 4), plant sterol and / or plant sterol fatty acid ester The oil phase is emulsified in an aqueous phase using enzyme-treated egg yolk as an emulsifier (Patent Document 5), and a fat-soluble component (water-insoluble substance) is mixed with polyglycerin fatty acid ester, polyhydric alcohol and water. Examples include solubilization methods (Patent Document 6) and fat-soluble components emulsified using an oil phase component, a polyhydric alcohol and an emulsifier (Patent Documents 7 and 8).
しかしながら、脂溶性成分には様々な種類があり、水への溶解性を始め、その性質や特性は脂溶性成分の種類に応じて様々である。従って、乳化・可溶化方法も、対象とする脂溶性成分の性質や特性に応じて具体的に検討し、個々の脂溶性成分に対して好適な方法を確立することが必要である。また、脂溶性成分が生理活性作用を有する場合には、水への溶解性に加えて、当該脂溶性成分の生理活性作用を最大限活用するために、生体内への吸収性を改善し向上させることも必要である。
本発明は、保存安定性に優れ、また水に対する溶解性または分散性に優れたコエンザイムQ10含有乳化組成物を提供することを目的とする。また、本発明は生体への吸収性、特に経口吸収性に優れたコエンザイムQ10含有乳化組成物を提供することを目的とする。さらに本発明は、コエンザイムQ10を安定に含有する各種の製品、特に水性の液状製品を提供することを目的とする。さらにまた本発明は、コエンザイムQ10について、その乳化安定性や水に対する溶解性または分散性を改善し向上させる方法、体内吸収性を改善し向上させる方法、及び体内抗酸化能を向上させる方法を提供することを目的とする。The present invention is excellent in storage stability, and also aims to provide a coenzyme Q 10 containing emulsion composition excellent in solubility or dispersibility in water. Further, the present invention aims to provide an absorbent, coenzyme Q 10 containing emulsion composition particularly excellent in oral absorption into the living body. The present invention aims at providing a liquid product of various products, particularly aqueous, containing the coenzyme Q 10 stably. Furthermore, the present invention is, for coenzyme Q 10, a method of improving improve the solubility or dispersibility in the emulsion stability and water, a method of improving improve bodily absorbability, and a method for improving the in-vivo antioxidant capacity The purpose is to provide.
本発明者らは、上記目的を達成するために鋭意検討していたところ、コエンザイムQ10に対して、特定量の中鎖トリグリセライドを、界面活性剤、多価アルコール及び水と共に配合して調製した乳化組成物が、水との相溶性に優れており、水と混合した場合に、高い透明性をもって溶解または分散することを見出した。さらに、当該乳化組成物は保存安定性に優れており、長期保存後も上記効果を安定して保持していることが確認された。また本発明者らは、上記の組成からなるコエンザイムQ10含有乳化組成物が、生体吸収性、特に経口投与による体内吸収性に優れており、体内抗酸化に有効に働くことを見いだした。本発明はこれらの知見に基づいて完成されたものである。The present inventors have had extensive studies in order to achieve the above object, relative coenzyme Q 10, a specific amount of medium chain triglyceride, a surfactant, it was prepared by blending together the polyhydric alcohol and water It has been found that the emulsified composition is excellent in compatibility with water and dissolves or disperses with high transparency when mixed with water. Furthermore, the emulsified composition was excellent in storage stability, and it was confirmed that the above effect was stably maintained even after long-term storage. The present inventors have found that the above-described a composition coenzyme Q 10 containing emulsion composition, bioabsorbable, excellent in vivo absorbability particularly by oral administration, has been found to work effectively in the body antioxidant. The present invention has been completed based on these findings.
すなわち、本発明は下記の態様を備えるものである。 That is, the present invention includes the following aspects.
(1)乳化組成物
項1.コエンザイムQ10、中鎖トリグリセライド、界面活性剤、多価アルコール及び水を含有し、コエンザイムQ1010重量部に対する中鎖トリグリセライドの割合が1〜10重量部、組成物100重量%に含まれる水の割合が10〜40重量%である、乳化組成物。
項2.コエンザイムQ1010重量部に対する水の割合が10〜40重量部である、項1記載の乳化組成物。
項3.中鎖トリグリセライドが、カプロン酸トリグリセライド、カプリル酸トリグリセライド、カプリン酸トリグリセライド、ラウリン酸トリグリセライド、カプロン酸/カプリル酸混合トリグリセライド、及びカプロン酸/カプリル酸/ラウリン酸混合トリグリセライドよりなる群から選択される少なくとも1種である、項1または2記載の乳化組成物。
項4.界面活性剤がHLB10以上のグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種である項1乃至3のいずれかに記載の乳化組成物。
項5.コエンザイムQ1010重量部に対する界面活性剤の割合が5〜20重量部である、項1乃至4のいずれかに記載の乳化組成物。
項6.界面活性剤が、レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種とHLB10以上のグリセリン脂肪酸エステルとの組合せ物である項1乃至5のいずれかに記載の乳化組成物。
項7.レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種を総量で0.01〜5重量%、グリセリン脂肪酸エステルを5〜20重量%の割合で含有する、項6記載の乳化組成物。
項8.項1乃至7のいずれかに記載する乳化組成物を固形化処理することによって調製される、固体状態の乳化組成物。(1)
Item 7. A term containing at least one selected from the group consisting of lecithin, enzyme-decomposed lecithin, fractionated lecithin, and enzyme-treated lecithin in a total amount of 0.01 to 5% by weight and glycerin fatty acid ester in a proportion of 5 to 20% by
Item 8. Item 8. A solid emulsion composition prepared by solidifying the emulsion composition according to any one of
(2)乳化組成物を含有する製品
項9.項1乃至8のいずれかに記載する乳化組成物を含有する製品。
項10.項1乃至8のいずれかに記載する乳化組成物を水に可溶化または分散させて調製される水性製品である、請求項9記載の製品。
項11.食品、医薬品、医薬部外品、化粧品または飼料のいずれかである、項9または10に記載する製品。
項12.ヒトに用いられる食品、医薬品または医薬部外品である、項9または10に記載する製品。(2) Item 9 containing an
Item 11. Item 11. The product according to
Item 12. Item 11. The product according to
(3)コエンザイムQ10を水に透明な状態で可溶化または分散させる方法
項13.項1乃至8のいずれかに記載する乳化組成物を水に可溶化または分散させることを特徴とする、コエンザイムQ10を水に透明な状態で可溶化または分散させる方法。(3) a method of Coenzyme Q 10 is solubilized or dispersed in a transparent state in water in claim 13. The emulsified composition according to any one of
(4)コエンザイムQ10の体内吸収性を高める方法
項14.コエンザイムQ10を含有する経口投与組成物において、コエンザイムQ10に中鎖トリグリセライド、界面活性剤、多価アルコール及び水を配合し、コエンザイムQ1010重量部に対する中鎖トリグリセライドの割合を1〜10重量部とする、コエンザイムQ10を含有する経口投与組成物の体内でのコエンザイムQ10の吸収性を高める方法。
項15.上記経口投与組成物が、コエンザイムQ10に中鎖トリグリセライド、界面活性剤、多価アルコール及び水を配合した経口投与組成物を、さらに固形化処理によって固体状にしたものである、項14記載の方法。
項16.経口投与組成物がヒトに用いられる経口投与組成物であって、ヒト体内でのコエンザイムQ10の吸収性を高める方法である、項14または15に記載する方法。
項17.中鎖トリグリセライドが、カプロン酸トリグリセライド、カプリル酸トリグリセライド、カプリン酸トリグリセライド、ラウリン酸トリグリセライド、カプロン酸/カプリル酸混合トリグリセライド、及びカプロン酸/カプリル酸/ラウリン酸混合トリグリセライドよりなる群から選択される少なくとも1種である、項14乃至16のいずれかに記載する方法。
項18.界面活性剤がHLB10以上のグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種である項14乃至17のいずれかに記載する方法。
項19.コエンザイムQ1010重量部に対する界面活性剤の割合が5〜20重量部である、項14乃至18のいずれかに記載する方法。
項20.界面活性剤が、レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種とHLB10以上のグリセリン脂肪酸エステルとの組合せ物である項14乃至19のいずれかに記載する方法。
項21.レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種を総量で0.01〜5重量%、グリセリン脂肪酸エステルを5〜20重量%の割合で含有する、項14乃至20のいずれかに記載する方法。(4) The method claim 14 to increase the systemic absorption of coenzyme Q 10. In oral compositions containing Coenzyme Q 10, a medium chain triglyceride to the coenzyme Q 10, a surfactant, a polyhydric alcohol and water were blended, 1-10 weight ratio of medium-chain triglycerides for coenzyme Q 10 10 parts by weight the parts, a method of enhancing the absorbability of coenzyme Q 10 in the body of an oral dosage composition containing a coenzyme Q 10.
Item 16. Oral dosage compositions are an oral dosage composition for use in humans, a method of increasing the absorption of coenzyme Q 10 in human body, the method described in
Item 17. The medium chain triglyceride is at least one selected from the group consisting of caproic acid triglyceride, caprylic acid triglyceride, capric acid triglyceride, lauric acid triglyceride, caproic acid / caprylic acid mixed triglyceride, and caproic acid / caprylic acid / lauric acid mixed triglyceride Item 17. The method according to any one of Items 14 to 16, wherein
Item 18. Item 18. The surfactant according to any one of Items 14 to 17, wherein the surfactant is at least one selected from the group consisting of glycerin fatty acid ester of
Item 21. A term containing at least one selected from the group consisting of lecithin, enzyme-decomposed lecithin, fractionated lecithin, and enzyme-treated lecithin in a total amount of 0.01 to 5% by weight and glycerin fatty acid ester in a proportion of 5 to 20% by weight The method according to any one of 14 to 20.
(5)コエンザイムQ10の体内抗酸化能を高める方法
項22.コエンザイムQ10を含有する経口投与組成物において、コエンザイムQ10に中鎖トリグリセライド、界面活性剤、多価アルコール及び水を配合し、コエンザイムQ1010重量部に対する中鎖トリグリセライドの割合を1〜10重量部とすることを特徴とする、コエンザイムQ10を含有する経口投与組成物について体内抗酸化力を高める方法。
項23.上記経口投与組成物が、コエンザイムQ10に中鎖トリグリセライド、界面活性剤、多価アルコール及び水を配合した経口投与組成物を、さらに固形化処理によって固体状にしたものである、項22記載の方法。
項24.経口投与組成物がヒトに用いられる経口投与組成物であって、ヒト体内の抗酸化力を高める方法である、項22または23記載の方法。(5) The method claim 22 to increase the body antioxidant capacity of coenzyme Q 10. In oral compositions containing Coenzyme Q 10, a medium chain triglyceride to the coenzyme Q 10, a surfactant, a polyhydric alcohol and water were blended, 1-10 weight ratio of medium-chain triglycerides for coenzyme Q 10 10 parts by weight characterized in that the parts, a method of increasing the body antioxidant capacity for oral compositions containing coenzyme Q 10.
Item 23. Said orally administered composition, the medium chain triglyceride to the coenzyme Q 10, a surfactant, a polyhydric alcohol and oral compositions containing water, in which further the solid by solid process, claim 22, wherein Method.
Item 24. Item 24. The method according to Item 22 or 23, wherein the composition for oral administration is an composition for oral administration used for humans, which is a method for enhancing antioxidant power in the human body.
(6)中鎖トリグリセライド、界面活性剤、多価アルコール及び水の使用
項25.水への溶解性および分散性の高いコエンザイムQ10含有乳化組成物の製造における、中鎖トリグリセライド、界面活性剤、多価アルコール及び水の使用。
項26.体内吸収性の高いコエンザイムQ10含有乳化組成物の製造における、中鎖トリグリセライド、界面活性剤、多価アルコール及び水の使用。
項27.体内吸収性が、ヒト体内での吸収性である項26記載の使用。(6) Use of medium chain triglyceride, surfactant, polyhydric alcohol and
Item 26. In the manufacture of the body highly absorbent coenzyme Q 10 containing emulsion composition, medium chain triglycerides, surfactants, use of a polyhydric alcohol and water.
Item 27. Item 27. The use according to Item 26, wherein the absorbability in the body is absorbability in the human body.
(7)抗酸化剤
項28.請求項1乃至8のいずれかに記載する乳化組成物を有効成分とする抗酸化剤。(7) Antioxidant Item 28. The antioxidant which uses the emulsion composition in any one of
本発明のコエンザイムQ10含有乳化組成物によれば、水との相溶性が高いため、水に良好に溶解または分散して、コエンザイムQ10を含有する透明な水溶液を調製することができる。さらに本発明のコエンザイムQ10含有乳化組成物は、保存安定性に優れており、上記効果を長期間にわたって維持している。また本発明のコエンザイムQ10含有乳化組成物は、生体への吸収性に優れているという特徴を有している。さらに本発明のコエンザイムQ10含有乳化組成物は、生体への吸収性に優れてため、優れた体内抗酸化能を発揮するという特徴を有している。According to coenzyme Q 10 containing emulsion composition of the present invention, the compatibility with water is high, the water was well dissolved or dispersed, can be prepared a clear aqueous solution containing Coenzyme Q 10. Further coenzyme Q 10 containing emulsion composition of the present invention is excellent in storage stability, it is maintained for a long period of time the effect. The Coenzyme Q 10 containing emulsion composition of the present invention is characterized of excellent absorption into the living body. Further coenzyme Q 10 containing emulsion composition of the present invention, since an excellent absorption into the living body, has a characteristic that exhibits an excellent body antioxidant activity.
従って、本発明のコエンザイムQ10含有乳化組成物は、例えば水を含む食品、化粧品、医薬品、医薬部外品及び飼料などの水性の製品に対しても製品の性状や品質に悪影響を与えることなく、安定して配合使用することができる。また、当該組成物はコエンザイムQ10の生体吸収性が高められているため、食品、化粧品、医薬品、医薬部外品及び飼料において、コエンザイムQ10の有する生理活性作用を充分に発揮させることが可能となる。Thus, coenzyme Q 10 containing emulsion composition of the present invention, for example, foods containing water, cosmetics, pharmaceuticals, without adversely affecting the properties and quality of the products in aqueous products such as quasi-drugs and feed , Can be used stably. Further, since the composition is enhanced bioabsorbable of coenzyme Q 10, food, cosmetics, pharmaceuticals, in quasi-drugs and feed, can be sufficiently exhibited physiologically active having a coenzyme Q 10 It becomes.
(1)コエンザイムQ10含有乳化組成物
本発明の乳化組成物は、コエンザイムQ10に加えて、中鎖グリセライド、界面活性剤、多価アルコール及び水を含有する。(1) coenzyme Q 10 emulsion composition containing the emulsion composition present invention, in addition to coenzyme Q 10, comprising medium chain glycerides, surfactants, polyhydric alcohol and water.
ここでコエンザイムQ10は、2,3-ジメトキシ-5-メチル-6-ポリプレニル-1,4-ベンオキノンの側鎖のイソプレノイド鎖(n)が10であるユビキノン類であり、別名、ユビデカレノン、補酵素Q10、CoQ10、補酵素UQ10とも呼ばれる脂溶性成分である。Here Coenzyme Q 10 is a
本発明に用いられるコエンザイムQ10は医薬又は食品として服用又は食用可能なコエンザイムQ10であればその由来および製法は何ら限定されるものでは無い。例えば、特開昭54−122795号公報または特開昭55−19006号公報に記載の方法により製造することができる。Its origin and production method as long Coenzyme Q 10 used in the present invention is a dose or edible coenzyme Q 10 as a pharmaceutical or food is not limited in any way. For example, it can be produced by the method described in JP-A No. 54-122955 or JP-A No. 55-19006.
本発明の乳化組成物100重量%に含まれるコエンザイムQ10の割合としては、通常1〜50重量%を挙げることができる。好ましくは2〜20重量%、より好ましくは5〜15重量%、さらに好ましくは8〜12重量%であり、最も好ましくは9〜11重量%である。The proportion of coenzyme Q 10 contained in the emulsion composition 100 wt% of the present invention, mention may be made of 1 to 50 wt%. Preferably it is 2-20 weight%, More preferably, it is 5-15 weight%, More preferably, it is 8-12 weight%, Most preferably, it is 9-11 weight%.
乳化組成物中に占めるコエンザイムQ10の割合が50重量%を超えてあまりにも多くなると、保存安定性、水に添加した際の溶解性や分散性(透明性)、並びに生体への吸収性の向上といった本発明の効果を得るために必要な他の成分の配合割合が相対的に低下し、目的とする乳化組成物が得られなくなるおそれがある。一方、コエンザイムQ10の割合が1重量%よりあまりにも少なくなると、コエンザイムQ10が有する所望の機能を得るために、大量の乳化組成物が必要となるという問題が生じる。If the ratio of coenzyme Q 10 occupied in the emulsion composition becomes too much beyond 50% by weight, storage stability, water was when solubility and dispersibility of the additive (transparent), as well as to bioabsorbable The blending ratio of other components necessary for obtaining the effect of the present invention, such as improvement, may be relatively lowered, and the intended emulsion composition may not be obtained. On the other hand, when the ratio of coenzyme Q 10 is too less than 1 wt%, in order to obtain the desired function of the coenzyme Q 10, a large amount of problem emulsified composition is required occurs.
本発明で使用する中鎖トリグリセライド(Medium chain triglycerides)は、カプロン酸、カプリル酸、カプリン酸、およびラウリン酸などの炭素数6〜12、好ましくはカプロン酸やカプリル酸などの炭素数6〜10の中鎖脂肪酸からなるトリアシルグリセロールである。ここで、トリグリセライドを構成する3個の脂肪酸は全て同一であってもよいし(単純トリグリセライド)、また異なる脂肪酸の混合物(混合トリグリセライド)であってもよい。なお、これらは1種または2種以上を任意に組み合わせて使用することもできる。単純トリグリセライドの例として、カプロン酸トリグリセライド、カプリル酸トリグリセライド、カプリン酸トリグリセライド、ラウリン酸トリグリセライドを挙げることができる。好ましくはカプロン酸トリグリセライド、およびカプリル酸トリグリセライドである。混合トリグリセライドとして、脂肪酸としてカプロン酸とカプリル酸を含有するカプロン酸/カプリル酸混合トリグリセライド、脂肪酸としてカプロン酸とカプリル酸とラウリン酸を含有するカプロン酸/カプリル酸/ラウリン酸混合トリグリセライドを挙げることができる。中鎖トリグリセライドとして好ましくは混合トリグリセライド、特にカプロン酸/カプリル酸混合トリグリセライドである。 Medium chain triglycerides used in the present invention have 6 to 12 carbon atoms such as caproic acid, caprylic acid, capric acid and lauric acid, preferably 6 to 10 carbon atoms such as caproic acid and caprylic acid. Triacylglycerol consisting of medium chain fatty acids. Here, all three fatty acids constituting the triglyceride may be the same (simple triglyceride), or may be a mixture of different fatty acids (mixed triglyceride). In addition, these can also be used combining 1 type (s) or 2 or more types arbitrarily. Examples of simple triglycerides include caproic acid triglyceride, caprylic acid triglyceride, capric acid triglyceride, and lauric acid triglyceride. Caproic acid triglyceride and caprylic acid triglyceride are preferable. Examples of mixed triglycerides include caproic acid / caprylic acid mixed triglyceride containing caproic acid and caprylic acid as fatty acids, and caproic acid / caprylic acid / lauric acid mixed triglyceride containing caproic acid, caprylic acid and lauric acid as fatty acids. . The medium chain triglyceride is preferably a mixed triglyceride, particularly a caproic acid / caprylic acid mixed triglyceride.
本発明の効果である保存安定性、水への溶解性や分散性(透明性)、並びに生体への吸収性を十分発揮するためには、かかる中鎖トリグリセライドは、本発明の乳化組成物中、前述のコエンザイムQ1010重量部に対して1〜10重量部の割合で用いることが好ましい。より好ましくは1〜5重量部、さらに好ましくは1〜4重量部、最も好ましくは2〜4重量部の割合である。In order to sufficiently exhibit the storage stability, water solubility and dispersibility (transparency), and absorbability to the living body, which are the effects of the present invention, such a medium chain triglyceride is contained in the emulsion composition of the present invention. The coenzyme Q 10 is preferably used at a ratio of 1 to 10 parts by weight with respect to 10 parts by weight of the aforementioned coenzyme Q 10 . More preferred is 1 to 5 parts by weight, still more preferred is 1 to 4 parts by weight, and most preferred is 2 to 4 parts by weight.
本発明で使用する界面活性剤は、食品、医薬品および化粧品の分野で乳化剤や分散剤として広く使われているものであればよく特に制限されない。好ましくは、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル、プロピレングリコール脂肪酸エステル、有機酸モノグリセライド、ポリグリセリン脂肪酸エステル;レシチン、分別レシチン、酵素分解レシチン、酵素処理レシチン等のリン脂質;キラヤ抽出物、エンジュサポニン、大豆サポニン、酵素処理大豆サポニン、茶種子サポニン、ユッカフォーム抽出物等のサポニン;ポリソルベート(ポリソルベート20、60、65、80);アラビアガム;加工デンプン、大豆食物繊維、キサンタンガム等を例示することができる。好ましくはグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、リン脂質、サポニン、ポリソルベート、又はアラビアガムである。より好ましくはグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、又はリン脂質である。なお、これらは1種または2種以上を任意に組み合わせて使用することもでき、例えば、組み合わせ態様として、グリセリン脂肪酸エステル及びリン脂質の組み合わせを好適に挙げることができる。
The surfactant used in the present invention is not particularly limited as long as it is widely used as an emulsifier or a dispersant in the fields of food, medicine and cosmetics. Preferably, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, organic acid monoglyceride, polyglycerin fatty acid ester; phospholipid such as lecithin, fractionated lecithin, enzymatically decomposed lecithin, enzyme-treated lecithin; kiraya extract Saponins such as Enjusaponin, Soy Saponin, Enzyme-treated Soy Saponin, Tea Seed Saponin, Yucca Foam Extract; Polysorbate (
ここでグリセリン脂肪酸エステルおよびショ糖脂肪酸エステルとしては、特に制限されるものではないが、HLB10以上のものが望ましく、例えばHLB10〜16のものを挙げることができる。グリセリン脂肪酸エステルとして、好適には炭素数12〜22、重合度5以上であるポリグリセリン脂肪酸エステル、具体的にはデカグリセリンラウリン酸エステル、デカグリセリンミリスチン酸エステル、デカグリセリンパルミチン酸エステル、デカグリセリンステアリン酸エステル、デカグリセリンオレイン酸エステル、デカグリセリンリノール酸エステル、デカグリセリンリノレン酸エステル、デカグリセリンアラキジン酸エステル、デカグリセリンエイコセン酸エステル、デカグリセリンベヘニン酸エステルを挙げることができる。好ましくは、デカグリセリンステアリン酸エステル、デカグリセリンオレイン酸エステル、デカグリセリンミリスチン酸エステル、またはデカグリセリンパルミチン酸エステルであり、より好ましくはデカグリセリンステアリン酸エステル、またはデカグリセリンオレイン酸エステルである。 Here, the glycerin fatty acid ester and the sucrose fatty acid ester are not particularly limited, but those having HLB of 10 or more are desirable, and examples thereof include those having HLB of 10 to 16. As the glycerin fatty acid ester, preferably a polyglycerin fatty acid ester having 12 to 22 carbon atoms and a polymerization degree of 5 or more, specifically decaglycerin lauric acid ester, decaglycerin myristic acid ester, decaglycerin palmitic acid ester, decaglycerin stearin Examples include acid esters, decaglycerin oleic acid esters, decaglycerin linoleic acid esters, decaglycerin linolenic acid esters, decaglycerin arachidic acid esters, decaglycerin eicosenoic acid esters, and decaglycerin behenic acid esters. Preferred are decaglycerin stearic acid ester, decaglycerin oleic acid ester, decaglycerin myristic acid ester, or decaglycerin palmitic acid ester, and more preferred are decaglycerin stearic acid ester or decaglycerin oleic acid ester.
またショ糖脂肪酸エステルとして、具体的にはショ糖モノパルミチン酸エステル、ショ糖モノステアリン酸モノエステル、ショ糖モノオレイン酸エステルを挙げることができる。 Specific examples of sucrose fatty acid esters include sucrose monopalmitate, sucrose monostearate monoester, and sucrose monooleate.
リン脂質として、好ましくは酵素処理レシチン、酵素分解レシチン、レシチン、分別レシチンを挙げることができる。より好ましくは酵素分解レシチン、レシチンであり、最も好ましくは酵素分解レシチンである。ここで酵素処理レシチンは、「植物レシチン」又は「卵黄レシチン」とグリセリンの混合物に、ホスホリパーゼDを作用させて得られたものであり、主成分としてホスファチジルグリセロールを含む。また酵素分解レシチンは、「植物レシチン」又は「卵黄レシチン」を、水又はアルカリ性水溶液でpH調整した後、室温時〜温時酵素分解し、次いでエタノール、イソプロピルアルコール若しくはアセトンで抽出して得られたものである。主成分としてリゾレシチン及びフォスファチジン酸を含む。 Preferred examples of the phospholipid include enzyme-treated lecithin, enzyme-decomposed lecithin, lecithin, and fractionated lecithin. More preferred are enzymatically degraded lecithin and lecithin, and most preferred is enzymatically degraded lecithin. Here, the enzyme-treated lecithin is obtained by allowing phospholipase D to act on a mixture of “plant lecithin” or “egg yolk lecithin” and glycerin, and includes phosphatidylglycerol as a main component. The enzymatically decomposed lecithin was obtained by adjusting the pH of “plant lecithin” or “egg yolk lecithin” with water or an alkaline aqueous solution, followed by enzymatic decomposition at room temperature to warm temperature, and then extracting with ethanol, isopropyl alcohol or acetone. Is. Contains lysolecithin and phosphatidic acid as main components.
サポニンとして、好ましくはキラヤ抽出物、エンジュサポニン、ダイズサポニン、酵素処理ダイズサポニン、茶種子サポニン、ビートサポニン、及びユッカ抽出物を挙げることが出来る。 Preferred examples of saponins include Kiraya extract, Enjusaponin, soybean saponin, enzyme-treated soybean saponin, tea seed saponin, beet saponin, and yucca extract.
ポリソルベートとしては、具体的にはポリソルベート20、ポリソルベート60、ポリソルベート65及びポリソルベート80が知られており、一般にも市販されている。本発明においてはこれらを1種単独で使用してもよいし、または2種以上を組み合わせて使用することができる。
Specifically,
本発明においてコエンザイムQ10と混合して乳化組成物を調製するために使用される界面活性剤の割合としては、本発明の効果を奏することを限度として、特に制限されず、界面活性剤の種類に応じて適宜調節することができる。通常、界面活性剤は、本発明の乳化組成物に含まれるコエンザイムQ1010重量部に対して3重量部以上の割合で用いることができる。本発明の効果である保存安定性、水への溶解性や分散性(透明性)、並びに生体への吸収性を十分発揮するという観点から、下限値としては、好ましくは5重量部以上、より好ましくは8重量部以上、さらに好ましくは10重量部以上の割合であり、上限値としては、好ましくは20重量部以下、より好ましくは15重量部以下、さらに好ましくは12重量部以下の割合で用いることができる。The proportion of the surfactant used to prepare the emulsified composition was mixed with coenzyme Q 10 in the present invention, a limit that the effects of the present invention is not particularly limited, the type of surfactant It can be adjusted as appropriate according to the conditions. Usually, the surfactant can be used at a ratio of 3 parts by weight or more with respect to 10 parts by weight of Coenzyme Q 10 contained in the emulsion composition of the present invention. From the viewpoint of sufficiently exhibiting storage stability, solubility in water and dispersibility (transparency), and absorbability to living bodies, which are the effects of the present invention, the lower limit is preferably 5 parts by weight or more, more The ratio is preferably 8 parts by weight or more, more preferably 10 parts by weight or more, and the upper limit is preferably 20 parts by weight or less, more preferably 15 parts by weight or less, and even more preferably 12 parts by weight or less. be able to.
一例を挙げると、グリセリン脂肪酸エステルとリン脂質を組み合わせて使用する場合、本発明の乳化組成物に含まれるコエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合としては、5〜20重量部、より好ましくは5〜15重量部、さらに好ましくは8〜15重量部、最も好ましくは8〜12重量部が挙げられる。As an example, when a glycerin fatty acid ester and a phospholipid are used in combination, the ratio of the glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 contained in the emulsified composition of the present invention is preferably 5 to 20 parts by weight. 5 to 15 parts by weight, more preferably 8 to 15 parts by weight, and most preferably 8 to 12 parts by weight.
またこの組み合わせの場合の、本発明の乳化組成物に含まれるコエンザイムQ1010重量部に対するリン脂質の割合の下限値としては、好ましくは0.01重量部以上、より好ましくは0.1重量部以上、さらに好ましくは0.2重量部以上、最も好ましくは0.3重量部以上の割合であり、上限値としては、好ましくは20重量部以下、より好ましくは10重量部以下、さらに好ましくは1重量部以下、最も好ましくは0.5重量部以下の割合で用いることができる。In this combination, the lower limit of the ratio of phospholipid to 10 parts by weight of Coenzyme Q 10 contained in the emulsion composition of the present invention is preferably 0.01 parts by weight or more, more preferably 0.1 parts by weight. More preferably, the ratio is 0.2 parts by weight or more, most preferably 0.3 parts by weight or more, and the upper limit is preferably 20 parts by weight or less, more preferably 10 parts by weight or less, and still more preferably 1 It can be used in a proportion of not more than parts by weight, most preferably not more than 0.5 parts by weight.
本発明でいう多価アルコールには、グリセリン、ジグリセリン、トリグリセリン、ポリグリセリン、プロピレングリコール、ジプロピレングリコール、1,3−ブチレングリコール、エチレングリコール、およびポリエチレングリコールのほか、ソルビトール、キシリトール、マルチトール、エリスリトール、およびマンニトール等の糖アルコール、ならびにキシロース、グルコース、ラクトース、マンノース、オリゴトース、果糖ブドウ糖液糖、およびシュクロース等の糖類が含まれる。好ましくは、グリセリン、プロピレングリコール、ソルビトール、マンニトール、グルコース、ラクトース、オリゴトース、果糖ブドウ糖液糖、シュクロースであり、さらに好ましくはグリセリン、果糖ブドウ糖液糖である。これらは1種単独で使用することもできるが、2種以上を任意に組み合わせて使用することもできる。 Examples of the polyhydric alcohol in the present invention include glycerin, diglycerin, triglycerin, polyglycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, ethylene glycol, and polyethylene glycol, as well as sorbitol, xylitol, and maltitol. , Sugar alcohols such as erythritol, and mannitol, and sugars such as xylose, glucose, lactose, mannose, oligotose, fructose glucose liquid sugar, and sucrose. Preferred are glycerin, propylene glycol, sorbitol, mannitol, glucose, lactose, oligotose, fructose glucose liquid sugar and sucrose, and more preferred are glycerin and fructose glucose liquid sugar. These can be used singly or in combination of two or more.
本発明においてコエンザイムQ10と混合して乳化組成物を調製するために使用される多価アルコールの割合としては、本発明の効果を奏することを限度として、特に制限されず、多価アルコールの種類に応じて適宜調節することができる。通常、多価アルコールは、本発明の乳化組成物に含まれるコエンザイムQ1010重量部に対して30〜80重量部の割合で用いることができる。本発明の効果である保存安定性、水への溶解性や分散性(透明性)、並びに生体への吸収性を十分発揮するという観点から、下限値としては、好ましくは40重量部以上、より好ましくは43重量部以上、さらに好ましくは45重量部以上の割合であり、上限値としては、好ましくは70重量部以下、より好ましくは60重量部以下、さらに好ましくは55重量部以下の割合で用いることができる。一例を挙げると、グリセリンを単独で用いる場合、40〜50重量部の割合が好ましく、グリセリンと果糖ブドウ糖液糖を組み合わせる場合は、45〜60重量部の割合が好ましい。The proportion of the polyhydric alcohol used to prepare the emulsified composition was mixed with coenzyme Q 10 in the present invention, a limit that the effects of the present invention is not particularly limited, the polyhydric alcohol type It can be adjusted as appropriate according to the conditions. Usually, polyhydric alcohols may be used in a proportion of 30 to 80 parts by weight relative to Coenzyme Q 10 10 parts by weight contained in the emulsion composition of the present invention. From the viewpoint of sufficiently exhibiting storage stability, water solubility and dispersibility (transparency), and absorbability to the living body, which are the effects of the present invention, the lower limit is preferably 40 parts by weight or more. The ratio is preferably 43 parts by weight or more, more preferably 45 parts by weight or more, and the upper limit is preferably 70 parts by weight or less, more preferably 60 parts by weight or less, and even more preferably 55 parts by weight or less. be able to. For example, when glycerin is used alone, a proportion of 40 to 50 parts by weight is preferred, and when glycerin and fructose-glucose liquid sugar are combined, a proportion of 45 to 60 parts by weight is preferred.
これらの成分を、公知の乳化方法を用いて、水とともに乳化組成物とすることで、本発明の乳化組成物を得ることができる。乳化組成物中の水の割合としては、特に制限されないが、通常10〜40重量%、好ましくは15〜35重量%、より好ましくは15〜25重量%を挙げることができる。また、乳化組成物に含まれるコエンザイムQ1010重量部に対する水の割合として、通常10〜40重量部、好ましくは15〜35重量部を挙げることができる。By making these components into an emulsified composition together with water using a known emulsification method, the emulsified composition of the present invention can be obtained. Although it does not restrict | limit especially as a ratio of the water in an emulsion composition, Usually, 10 to 40 weight%, Preferably it is 15 to 35 weight%, More preferably, 15 to 25 weight% can be mentioned. Further, as the ratio of water to
なお、本発明の乳化組成物には、本発明の効果を妨げない範囲において、上記成分に加えてさらに抗酸化剤、キレート剤、色素、香料、甘味料、無機酸や有機酸、又は増粘多糖類を配合することができる。 The emulsified composition of the present invention includes an antioxidant, a chelating agent, a dye, a fragrance, a sweetener, an inorganic acid or an organic acid, or a thickening agent, in addition to the above components, within a range that does not interfere with the effects of the present invention. Polysaccharides can be blended.
制限はされないが、抗酸化剤としては、例えばミックストコフェロール等の抽出トコフェロール、ビタミンC、水溶性ポリフェノール等;キレート剤としては、例えば重合リン酸塩、フィチン酸等;色素としては、β-カロテン、リコピン等の脂溶性色素又は水溶性色素;香料としては、オレンンジ、グレープフルーツ、レモン等の柑橘製油類や合成香料等;甘味料としては、砂糖等の甘味料や高甘味度甘味料;無機酸や有機酸としては、クエン酸、リンゴ酸、酒石酸、乳酸、フィチン酸、燐酸、コハク酸、酢酸、グルコン酸、グルタミン酸、塩酸、ポリ燐酸を;増粘多糖類としては、デキストリン、シクロデキストリン、アラビアガム、キサンタンガム、グァーガム等を挙げることができる。中でも、抗酸化剤の添加は好ましく、とりわけ抽出トコフェロールの添加を好適な例として挙げることができる。 Although not limited, as an antioxidant, for example, extracted tocopherol such as mixed tocopherol, vitamin C, water-soluble polyphenol and the like; as a chelating agent, for example, polymerized phosphate, phytic acid, etc .; as a pigment, β-carotene, Fat-soluble pigments such as lycopene or water-soluble pigments; as perfumes, citrus oils such as oranges, grapefruits, lemons, and synthetic perfumes; as sweeteners, sweeteners such as sugar and high-intensity sweeteners; inorganic acids and Organic acids include citric acid, malic acid, tartaric acid, lactic acid, phytic acid, phosphoric acid, succinic acid, acetic acid, gluconic acid, glutamic acid, hydrochloric acid, and polyphosphoric acid; thickening polysaccharides include dextrin, cyclodextrin, and gum arabic , Xanthan gum, guar gum and the like. Among these, addition of an antioxidant is preferable, and addition of extracted tocopherol can be mentioned as a suitable example.
以上説明するように、本発明のコエンザイムQ10含有乳化組成物は、コエンザイムQ10に加えて、中鎖グリセライド、界面活性剤、多価アルコール及び水を含有することを特徴とする。その具体的に好適な組み合わせを以下に挙げる。As described above, coenzyme Q 10 containing emulsion composition of the present invention, in addition to coenzyme Q 10, a medium chain glyceride, a surfactant, characterized by containing a polyhydric alcohol and water. Specific preferred combinations thereof are listed below.
(1)コエンザイムQ10、中鎖トリグリセライド、界面活性剤、多価アルコール及び水を含有し、コエンザイムQ1010重量部に対する中鎖トリグリセライドの割合が1〜10重量部、組成物100重量%に含まれる水の割合が10〜40重量%である、乳化組成物。
(2)コエンザイムQ1010重量部に対する水の割合が10〜40重量部である、上記(1)記載の乳化組成物。
(3)中鎖トリグリセライドが、カプロン酸トリグリセライド、カプリル酸トリグリセライド、カプリン酸トリグリセライド、ラウリン酸トリグリセライド、カプロン酸/カプリル酸混合トリグリセライド、及びカプロン酸/カプリル酸/ラウリン酸混合トリグリセライドよりなる群から選択される少なくとも1種である、上記(1)又は(2)記載の乳化組成物。
(4)中鎖トリグリセライドが、カプロン酸/カプリル酸混合トリグリセライドである上記(3)記載の乳化組成物。
(5)コエンザイムQ1010重量部に対するカプロン酸/カプリル酸混合トリグリセライドの割合が、1〜3重量部である上記(4)記載の乳化組成物。(1) Coenzyme Q 10 , medium chain triglyceride, surfactant, polyhydric alcohol and water are contained, and the ratio of medium chain triglyceride to 10 parts by weight of coenzyme Q 10 is 1 to 10 parts by weight, contained in 100% by weight of the composition An emulsified composition, wherein the proportion of water is from 10 to 40% by weight.
(2) The emulsion composition according to the above (1), wherein the ratio of water to 10 parts by weight of Coenzyme Q 10 is 10 to 40 parts by weight.
(3) The medium chain triglyceride is selected from the group consisting of caproic acid triglyceride, caprylic acid triglyceride, capric acid triglyceride, lauric acid triglyceride, caproic acid / caprylic acid mixed triglyceride, and caproic acid / caprylic acid / lauric acid mixed triglyceride The emulsion composition according to (1) or (2), which is at least one kind.
(4) The emulsion composition according to (3), wherein the medium chain triglyceride is a caproic acid / caprylic acid mixed triglyceride.
(5) The emulsion composition according to the above (4), wherein the ratio of caproic acid / caprylic acid mixed triglyceride to 10 parts by weight of coenzyme Q 10 is 1 to 3 parts by weight.
(6)コエンザイムQ1010重量部に対するカプロン酸/カプリル酸混合トリグリセライドの割合が、3重量部である上記(4)記載の乳化組成物。
(7)界面活性剤が、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、及びリン脂質よりなる群から選択される少なくとも1種である上記(1)〜(6)のいずれか1つに記載の乳化組成物。
(8)界面活性剤が、グリセリン脂肪酸エステル及びリン脂質である上記(7)記載の乳化組成物。
(9)界面活性剤が、レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種とHLB10以上のグリセリン脂肪酸エステルとの組合せ物である上記(8)に記載の乳化組成物。
(10)リン脂質が、酵素分解レシチンである上記(7)〜(9)のいずれか1つに記載の乳化組成物。(6) The emulsion composition according to (4), wherein the ratio of caproic acid / caprylic acid mixed triglyceride to 10 parts by weight of coenzyme Q 10 is 3 parts by weight.
(7) The emulsified composition according to any one of (1) to (6), wherein the surfactant is at least one selected from the group consisting of glycerin fatty acid ester, sucrose fatty acid ester, and phospholipid. object.
(8) The emulsion composition according to the above (7), wherein the surfactant is a glycerin fatty acid ester and a phospholipid.
(9) The surfactant is a combination of at least one selected from the group consisting of lecithin, enzyme-decomposed lecithin, fractionated lecithin, and enzyme-treated lecithin and a glycerin fatty acid ester of
(10) The emulsified composition according to any one of (7) to (9), wherein the phospholipid is enzyme-decomposed lecithin.
(11)グリセリン脂肪酸エステルが、デカグリセリンモノオレイン酸エステルである上記(10)記載の乳化組成物。
(12)界面活性剤が、グリセリン脂肪酸エステルである上記(7)記載の乳化組成物。
(13)グリセリン脂肪酸エステルが、デカグリセリンモノステアリン酸エステルである上記(12)記載の乳化組成物。
(14)コエンザイムQ1010重量部に対する界面活性剤の割合が5〜20重量部である、上記(7)〜(13)のいずれか1つに記載の乳化組成物。
(15)レシチン、酵素分解レシチン、分別レシチン、及び酵素処理レシチンよりなる群から選択される少なくとも1種を総量で0.01〜5重量%、グリセリン脂肪酸エステルを5〜20重量%の割合で含有する、上記(9)に記載の乳化組成物。(11) The emulsion composition according to the above (10), wherein the glycerin fatty acid ester is decaglycerin monooleate.
(12) The emulsion composition according to the above (7), wherein the surfactant is a glycerin fatty acid ester.
(13) The emulsion composition according to (12), wherein the glycerin fatty acid ester is decaglycerin monostearate.
(14) The emulsion composition according to any one of (7) to (13) above, wherein the ratio of the surfactant to 10 parts by weight of Coenzyme Q 10 is 5 to 20 parts by weight.
(15) Contains at least one selected from the group consisting of lecithin, enzyme-decomposed lecithin, fractionated lecithin, and enzyme-treated lecithin in a total amount of 0.01 to 5% by weight and glycerin fatty acid ester in a proportion of 5 to 20% by weight The emulsion composition according to (9) above.
(16)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が5〜15重量部であり、リン脂質の割合が0.1〜1重量部である、上記(8)〜(11)のいずれか1つに記載の乳化組成物。
(17)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が8〜15重量部であり、リン脂質の割合が0.1〜0.5重量部である、上記(8)〜(11)のいずれか1つに記載の乳化組成物。
(18)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が8〜12重量部であり、リン脂質の割合が0.2〜0.5重量部である、上記(8)〜(11)のいずれか1つに記載の乳化組成物。
(19)コエンザイムQ1010重量部に対するデカグリセリンモノオレイン酸エステルの割合が12重量部であり、酵素分解レシチンの割合が0.3重量部である、上記(11)記載の乳化組成物。
(20)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が5〜15重量部である、上記(12)又は(13)に記載の乳化組成物。(16) Any of (8) to (11) above, wherein the ratio of glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 5 to 15 parts by weight and the ratio of phospholipid is 0.1 to 1 part by weight The emulsified composition according to one.
(17) The ratio of glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 8 to 15 parts by weight, and the ratio of phospholipid is 0.1 to 0.5 parts by weight. The emulsified composition as described in any one.
(18) The ratio of glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 8 to 12 parts by weight, and the ratio of phospholipid is 0.2 to 0.5 parts by weight. The emulsified composition as described in any one.
(19) The emulsion composition according to the above (11), wherein the ratio of decaglycerin monooleate to 10 parts by weight of coenzyme Q 10 is 12 parts by weight and the ratio of enzymatically decomposed lecithin is 0.3 parts by weight.
(20) The emulsion composition according to (12) or (13) above, wherein the ratio of glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 5 to 15 parts by weight.
(21)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が8〜15重量部である、上記(12)又は(13)に記載の乳化組成物。
(22)コエンザイムQ1010重量部に対するグリセリン脂肪酸エステルの割合が8〜12重量部である、上記(12)又は(13)に記載の乳化組成物。
(23)コエンザイムQ1010重量部に対するデカグリセリンモノステアリン酸エステルの割合が8重量部である、上記(13)記載の乳化組成物。
(24)多価アルコールが、グリセリン及び果糖ブドウ糖液糖よりなる群から選択される少なくとも1種である上記(1)〜(23)のいずれか1つに記載の乳化組成物。
(25)多価アルコールが、グリセリン及び果糖ブドウ糖液糖である上記(24)記載の乳化組成物。(21) The emulsion composition according to (12) or (13) above, wherein the ratio of the glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 8 to 15 parts by weight.
(22) The emulsion composition according to the above (12) or (13), wherein the ratio of the glycerin fatty acid ester to 10 parts by weight of coenzyme Q 10 is 8 to 12 parts by weight.
(23) The emulsion composition according to the above (13), wherein the ratio of decaglycerin monostearate to 8 parts by weight of coenzyme Q 10 is 8 parts by weight.
(24) The emulsion composition according to any one of (1) to (23), wherein the polyhydric alcohol is at least one selected from the group consisting of glycerin and fructose-glucose liquid sugar.
(25) The emulsion composition according to the above (24), wherein the polyhydric alcohol is glycerin and fructose-glucose liquid sugar.
(26)コエンザイムQ1010重量部に対する多価アルコールの割合が40〜70重量部である、上記(24)又は(25)に記載の乳化組成物。
(27)コエンザイムQ1010重量部に対する多価アルコールの割合が43〜60重量部である、上記(24)又は(25)に記載の乳化組成物。
(28)コエンザイムQ1010重量部に対する多価アルコールの割合が47〜60重量部である、上記(24)又は(25)に記載の乳化組成物。
(29)コエンザイムQ1010重量部に対するグリセリン及び果糖ブドウ糖液糖の割合が等量部である、上記(26)〜(28)のいずれか1つに記載の乳化組成物。
(30)コエンザイムQ1010重量部に対するグリセリンの割合及び果糖ブドウ糖液糖の割合が共に27重量部である上記(29)記載の乳化組成物。
(31)多価アルコールが、グリセリンである上記(24)記載の乳化組成物。
(32)コエンザイムQ1010重量部に対するグリセリンの割合が43〜48重量部の割合である上記(31)記載の乳化組成物。(26) The emulsion composition according to (24) or (25) above, wherein the ratio of the polyhydric alcohol to 10 parts by weight of Coenzyme Q 10 is 40 to 70 parts by weight.
(27) The emulsion composition according to (24) or (25) above, wherein the ratio of the polyhydric alcohol to 10 parts by weight of coenzyme Q 10 is 43 to 60 parts by weight.
(28) The emulsion composition according to (24) or (25) above, wherein the ratio of the polyhydric alcohol to 10 parts by weight of Coenzyme Q 10 is 47 to 60 parts by weight.
(29) The emulsified composition according to any one of (26) to (28), wherein the ratio of glycerin and fructose-glucose liquid sugar to 10 parts by weight of coenzyme Q 10 is an equal part.
(30) The emulsion composition according to the above (29), wherein the ratio of glycerin and the ratio of fructose-glucose liquid sugar to 10 parts by weight of coenzyme Q 10 are both 27 parts by weight.
(31) The emulsion composition according to the above (24), wherein the polyhydric alcohol is glycerin.
(32) The emulsion composition according to the above (31), wherein the ratio of glycerin to 10 parts by weight of Coenzyme Q 10 is 43 to 48 parts by weight.
(33)上記(1)〜(32)いずれか1つに記載の乳化組成物に、さらに抗酸化物を添加した乳化組成物。
(34)抗酸化物が抽出トコフェノールである上記(33)記載の乳化組成物。
(35)コエンザイムQ1010重量部に対する抽出トコフェノールの割合が0.1重量部の割合である上記(34)記載の乳化組成物。
(36)組成物100重量%に含まれる水の割合が15〜35重量%である、上記(1)〜(35)いずれか1つに記載の乳化組成物。
(37)組成物100重量%に含まれる水の割合が15〜25重量%である、上記(1)〜(35)いずれか1つに記載の乳化組成物。
(38)上記(1)〜(37)いずれか1つに記載の乳化組成物を固形化処理することによって調製される、固体状態の乳化組成物。(33) An emulsion composition in which an antioxidant is further added to the emulsion composition according to any one of (1) to (32) above.
(34) The emulsion composition according to the above (33), wherein the antioxidant is extracted tocophenol.
(35) The emulsion composition according to the above (34), wherein the ratio of the extracted tocophenol to 10 parts by weight of coenzyme Q 10 is 0.1 parts by weight.
(36) The emulsion composition according to any one of (1) to (35) above, wherein the proportion of water contained in 100% by weight of the composition is 15 to 35% by weight.
(37) The emulsion composition according to any one of (1) to (35) above, wherein the proportion of water contained in 100% by weight of the composition is 15 to 25% by weight.
(38) A solid state emulsion composition prepared by solidifying the emulsion composition according to any one of (1) to (37) above.
(39)1gをイオン交換水100mlに添加して得られるコエンザイムQ10含有液の720nmにおける吸収光度が0.10以下であることを特徴とするコエンザイムQ10乳化組成物。
(40)720nmにおける吸収光度が0.09以下である上記(39)記載の乳化組成物。
(41)720nmにおける吸収光度が0.08以下である上記(39)記載の乳化組成物。
(42)720nmにおける吸収光度が0.04以下である上記(39)記載の乳化組成物。(39) coenzyme Q 10 emulsion composition absorption intensity at 720nm of coenzyme Q 10 containing liquid obtained by the 1g were added to ion-exchanged water 100ml is characterized in that 0.10 or less.
(40) The emulsion composition according to the above (39), wherein the absorbed light intensity at 720 nm is 0.09 or less.
(41) The emulsion composition according to the above (39), wherein the absorbed light intensity at 720 nm is 0.08 or less.
(42) The emulsion composition according to the above (39), wherein the absorbed light intensity at 720 nm is 0.04 or less.
乳化組成物の調製方法の一例を挙げると、コエンザイムQ10、中鎖トリグリセライド、及び界面活性剤を混合し、加熱して溶解し、次いでこの溶液を多価アルコール及び水と混合して乳化処理を行う。ここで溶解温度としては、通常50〜150℃、好ましくは50〜100℃を挙げることができる。乳化処理には通常の乳化装置、例えばパドルミキサー、アジホモミキサー、コロイドミル、高圧乳化機、高圧ホモゲナイザー、ホモジェッター等を制限なく使用することができる。乳化処理時の温度は、通常、常温〜80℃である。好ましくは15〜60℃、より好ましくは15〜40℃である。また乳化処理を高圧下で行う場合の圧力範囲は、制限はされないが、通常100〜5000kg/cm2、好ましくは500〜2000kg/cm2、より好ましくは500〜1000kg/cm2を挙げることができる。An example of a method for preparing an emulsified composition is as follows: Coenzyme Q 10 , medium chain triglyceride, and surfactant are mixed and dissolved by heating, and then this solution is mixed with polyhydric alcohol and water for emulsification treatment. Do. Here, the melting temperature is usually 50 to 150 ° C, preferably 50 to 100 ° C. For the emulsification treatment, an ordinary emulsification apparatus, for example, a paddle mixer, an azimuth homomixer, a colloid mill, a high-pressure emulsifier, a high-pressure homogenizer, or a homojetter can be used without limitation. The temperature during the emulsification treatment is usually from room temperature to 80 ° C. Preferably it is 15-60 degreeC, More preferably, it is 15-40 degreeC. The pressure range in the case of performing emulsification under high pressure, but are not limited, usually 100~5000kg / cm 2, preferably 500~2000kg / cm 2, more preferably be mentioned 500~1000kg / cm 2 .
斯くして製造される本発明の乳化組成物は、コエンザイムQ10を、均一に乳化された状態で安定的に含有している。当該本発明の乳化組成物は保存安定性に優れており、また水との相溶性が高いため、水に添加し混合すると良好に溶解または分散して、光学的に透明な水溶液を得ることもできる。さらに本発明の乳化組成物は、経口投与した場合の体内吸収性、特にヒトにおける経口投与時の体内吸収性にも優れているという特徴を有している。Emulsion composition of the present invention as thus to manufacture, contains a coenzyme Q 10, stably with uniformly emulsified state. The emulsified composition of the present invention has excellent storage stability and high compatibility with water, so that it can be dissolved or dispersed well when added to water and mixed to obtain an optically transparent aqueous solution. it can. Furthermore, the emulsified composition of the present invention has a feature that it is excellent in in vivo absorption when administered orally, particularly in in vivo absorption in humans.
本発明の乳化組成物は、その形状を特に問うものではない。例えば、上記で製造される溶液状態(乳液状態)であってもよいし、当該溶液が、ソフトカプセルやハードカプセルなどのカプセル基剤に封入されたカプセル剤の形状を有していてもよい。また、粉末状または顆粒状など任意の形態に固体成形化(固形化)された固体状態であってもよい。固形化の方法は特に制限されないが、上記で製造される溶液状態の乳化組成物(乳液)を、噴霧乾燥もしくは凍結乾燥等の常法に従って乾燥して粉末化する方法、または賦形剤に吸着若しくは担持させて粉末または顆粒状に固形化する方法などを挙げることができる。好ましくは前者の方法である。ここで賦形剤は、本発明の乳化組成物の特徴である水との相溶性(溶解性、分散性)を妨げないものであればよく、例えば、粉末乳糖、微結晶セルロース、コーンスターチ、デキストリン、β−サイクロデキストリン、単糖類、少糖類、糖アルコール、及び微粒二酸化ケイ素などの、経口摂取可能な従来公知の賦形剤の中から選択して用いることができる。なお、これらの粉末または顆粒状の乳化組成物は、さらにカプセル基剤に封入してカプセル状に調製してもよいし、打錠して錠剤状に調製することもできる。 The shape of the emulsified composition of the present invention is not particularly limited. For example, the solution state (milky solution state) produced above may be used, or the solution may have the form of a capsule encapsulated in a capsule base such as a soft capsule or a hard capsule. Further, it may be in a solid state that is solid-molded (solidified) into an arbitrary form such as powder or granule. The solidification method is not particularly limited, but the emulsion composition (emulsion) in the solution state produced above is dried and powdered according to a conventional method such as spray drying or freeze drying, or adsorbed on an excipient. Or the method of making it carry | support and solidifying to a powder or granule etc. can be mentioned. The former method is preferred. Here, the excipient may be any excipient as long as it does not interfere with water compatibility (solubility, dispersibility), which is a feature of the emulsion composition of the present invention. For example, powdered lactose, microcrystalline cellulose, corn starch, dextrin , Β-cyclodextrin, monosaccharides, oligosaccharides, sugar alcohols, finely divided silicon dioxide, and other conventionally known excipients that can be taken orally. In addition, these powder or granular emulsion compositions may be further encapsulated in a capsule base to prepare a capsule, or tableted to prepare a tablet.
なお、本発明の乳化組成物は、上記加工する過程で採用する物理的条件または共存する他の成分に応じて、コエンザイムQ10として、酸化型コエンザイムQ10から生じる還元型コエンザイムQ10を含有してもよい。Incidentally, the emulsified composition of the present invention, depending on the other components of physical conditions or co employed in the course of the processing, as coenzyme Q 10, containing reduced coenzyme Q 10 resulting from oxidized coenzyme Q 10 May be.
(2)コエンザイムQ10を含む各種製品
上記のようにして得られる本発明のコエンザイムQ10含有乳化組成物は、食品、化粧品、医薬品、医薬部外品および飼料などの各種製品、特に水を原料として調製される製品、水を含む製品、または水溶性の製品(これらの製品を「水性製品」と称する)に対して、コエンザイムQ10が有する機能(生理活性作用)を付与し、安定的に保持させる目的で有効に使用することができる。(2) coenzyme Q 10 containing emulsion composition of the present invention obtained as various products described above containing Coenzyme Q 10 is a food, cosmetics, pharmaceuticals, various products such as quasi-drugs and feed, in particular the water feed the product prepared as a product comprising water or to a water soluble products (these products referred to as "aqueous products"), imparts the function of the coenzyme Q 10 (physiological activity), stably It can be used effectively for the purpose of holding.
このため、本発明は、コエンザイムQ10を含有する各種の製品、具体的には、食品、化粧品、医薬品、医薬部外品、および飼料を提供する。好ましくは、ヒトに用いられる食品、化粧品、医薬品、および医薬部外品である。Therefore, the present invention provides a variety of products containing coenzyme Q 10, specifically, provides food, cosmetics, pharmaceuticals, quasi-drugs, and feed. Preferred are foods, cosmetics, pharmaceuticals, and quasi drugs used for humans.
これらの製品は、本発明のコエンザイムQ10含有乳化組成物からなるものであってもよいし、また本発明のコエンザイムQ10含有乳化組成物を、他の原料とともに、原料の一つとして含むものであってもよい。These products may be one consisting of coenzyme Q 10 containing emulsion composition present invention, also the coenzyme Q 10 containing emulsion composition of the present invention, together with other ingredients, which include as one of the raw materials It may be.
本発明が対象とする食品としては、例えば乳飲料、乳酸菌飲料、炭酸飲料、果実飲料(果汁飲料、果汁入り清涼飲料、果汁入り炭酸飲料、果肉飲料を含む)、野菜飲料、野菜・果実飲料、アルコール飲料、コーヒー飲料、粉末飲料、スポーツ飲料、サプリメント飲料等の飲料類;紅茶飲料、緑茶、ブレンド茶等の茶飲料類(以上、「飲料」と称する);カスタードプリン、ミルクプリン、果汁入りプリン等のプリン類、ゼリー、ババロア及びヨーグルト等のデザート類;ミルクアイスクリーム、果汁入りアイスクリーム及びソフトクリーム、アイスキャンディー等の冷菓類;チューインガムや風船ガム等のガム類(板ガム、糖衣状粒ガム);マーブルチョコレート等のコーティングチョコレートの他、イチゴチョコレート、ブルーベリーチョコレート及びメロンチョコレート等の風味を付加したチョコレート等のチョコレート類;ハードキャンディー(ボンボン、バターボール、マーブル等を含む)、ソフトキャンディー(キャラメル、ヌガー、グミキャンディー、マシュマロ等を含む)、ドロップ、タフィ等のキャラメル類;ハードビスケット、クッキー、おかき、煎餅等の焼き菓子類(以上、デザート類〜焼き菓子類まで全て包含して「菓子類」と称する);コンソメスープ、ポタージュスープ等のスープ類;浅漬け、醤油漬け、塩漬け、味噌漬け、粕漬け、麹漬け、糠漬け、酢漬け、芥子漬、もろみ漬け、梅漬け、福神漬、しば漬、生姜漬、梅酢漬け等の漬物類;セパレートドレッシング、ノンオイルドレッシング、ケチャップ、たれ、ソースなどのソース類;ストロベリージャム、ブルーベリージャム、マーマレード、リンゴジャム、杏ジャム、プレザーブ等のジャム類;赤ワイン等の果実酒;シロップ漬のチェリー、アンズ、リンゴ、イチゴ、桃等の加工用果実;ハム、ソーセージ、焼き豚等の畜肉加工品;魚肉ハム、魚肉ソーセージ、魚肉すり身、蒲鉾、竹輪、はんぺん、薩摩揚げ、伊達巻き、鯨ベーコン等の水産練り製品;バター、マーガリン、チーズ、ホイップクリーム等の酪農・油脂製品類;うどん、冷麦、そうめん、ソバ、中華そば、スパゲッティ、マカロニ、ビーフン、はるさめ及びワンタン等の麺類;その他、各種総菜及び麩、田麩等の種々の加工食品を挙げることができる。 Examples of foods targeted by the present invention include milk drinks, lactic acid bacteria drinks, carbonated drinks, fruit drinks (including fruit juice drinks, fruit juice soft drinks, fruit juice carbonated drinks, fruit drinks), vegetable drinks, vegetable / fruit drinks, Beverages such as alcoholic beverages, coffee beverages, powdered beverages, sports beverages and supplement beverages; tea beverages such as tea beverages, green tea and blended tea (hereinafter referred to as “beverages”); custard pudding, milk pudding, fruit pudding Desserts such as puddings such as jelly, bavaroa and yogurt; Ice cream and soft ice cream containing fruit juice, soft ice cream, ice candy and other confectionery; Gums such as chewing gum and bubble gum (plate gum, sugar-coated gum ); Coated chocolate such as marble chocolate, strawberry chocolate, blueberry chocolate Chocolates such as chocolate with flavor such as rate and melon chocolate; hard candy (including bonbon, butterball, marble, etc.), soft candy (including caramel, nougat, gummy candy, marshmallow, etc.), drop, toffee, etc. Caramels; hard biscuits, cookies, rice cakes, rice crackers and other baked confectionery (all desserts to baked confectionery are referred to as “confectionery”); consommé soups, potage soups, etc .; shallow Pickles, soy sauce pickles, pickles, salt pickles, miso pickles, pickled pickles, pickled pickles, pickled pickles such as pickled pickles, pickled pickles, shizu pickles, ginger pickles, pickled plums; separate dressing, non-oil dressing, ketchup Sauces, sauces, sauces, etc .; Strawberry Jams such as jam, blueberry jam, marmalade, apple jam, apricot jam, prasab; fruit wine such as red wine; fruit for processing cherries of syrup, apricots, apples, strawberries, peaches; ham, sausage, grilled pork, etc. Processed meat products; fish ham, fish sausage, fish surimi, salmon, bamboo rings, hampen, fried Satsuma, Date roll, whale bacon, etc .; dairy and fat products such as butter, margarine, cheese, whipped cream; udon , Noodles such as cold wheat, somen, buckwheat, Chinese noodles, spaghetti, macaroni, rice noodles, harsame and wonton; various other prepared foods and various processed foods such as rice cake and rice bran.
前述するように、本発明のコエンザイムQ10含有乳化組成物は、水に添加し混合した際の溶解性や分散性に優れ、さらに生体への吸収性にも優れているため、水を原料として調製されるか、水を含むか、または水溶性である、いわゆる水性の食品に対して有効に使用することができる。この点から、上記食品のうち好ましくは、例えば飲料、菓子類、漬物類、ソース類及びジャム類に属する水性食品である。より好ましくは飲料、果汁入りの菓子類、漬物類、果汁入りのソース類、及びジャム類である。As described above, coenzyme Q 10 containing emulsion composition of the present invention is excellent in solubility and dispersibility upon addition to water mixture, since the further excellent absorbability into a living body, water as a raw material It can be used effectively for so-called aqueous foods that are prepared, contain water or are water-soluble. From this viewpoint, among the above foods, for example, water-based foods belonging to beverages, confectionery, pickles, sauces and jams are preferable. More preferred are beverages, confectionery with fruit juice, pickles, sauces with fruit juice, and jams.
本発明のコエンザイムQ10を含有する食品は、製造の任意の工程で、原料の一つとして上記本発明のコエンザイムQ10含有乳化組成物を配合することによって製造することができる。この工程を除けば、各種食品に関する慣用の製造方法に従って製造することができる。よって、本発明の食品は、その製造に際して特別な製造装置や製造条件の設定を行う必要がないため、工業的にも有用である。Foods containing Coenzyme Q 10 of the present invention may be at any step of the manufacturing, prepared by blending a coenzyme Q 10 containing emulsion composition of the present invention as one of raw materials. If this process is excluded, it can manufacture according to the conventional manufacturing method regarding various foodstuffs. Therefore, the food of the present invention is industrially useful because it is not necessary to set a special production apparatus or production conditions in the production.
コエンザイムQ10含有食品の製造にあたり本発明のコエンザイムQ10含有乳化組成物の配合割合は、当該食品を通常量摂取することによって所望のコエンザイムQ10機能を奏すると考えられる量であれば特に制限されない。通常、食品100重量%中に含まれるコエンザイムQ10の割合として0.00001〜5重量%の範囲から、食品の種類に応じて適宜設定することができる。The mixing ratio of the coenzyme Q 10 containing emulsion composition of the present invention in the production of coenzyme Q 10 containing food is not particularly limited as long as it is an amount that would produce the desired coenzyme Q 10 function by conventional amounts ingested the food . Usually, the range of 0.00001% by weight as a percentage of Coenzyme Q 10 in food in 100 wt%, can be appropriately set according to the type of food.
本発明が対象とするコエンザイムQ10含有食品には、錠剤状、丸剤状、粉末状、顆粒状、カプセル状、および液状(ドリンク)といった各種の製剤形態を有するサプリメントが含まれる。かかるサプリメント製剤は、上記本発明の溶液状態(乳液状態)の乳化組成物またはこれを水などの水性溶媒に分散させたドリンクであっても、また本発明の溶液状態(乳液状態)の乳化組成物をソフトカプセルやハードカプセルなどのカプセル基剤に封入したカプセル製剤であってもよい。さらに、本発明の溶液状態(乳液状態)の乳化組成物を噴霧乾燥もしくは凍結乾燥したり、賦形剤に吸着若しくは担持させて固形化した粉末製剤または顆粒製剤であっても、またこれを打錠や圧縮して調製した錠剤や丸剤、さらにはカプセル基剤に封入したカプセル製剤であってもよい。Coenzyme Q 10 containing food to which the present invention is directed, tablet form, pills, powders, granules, capsules shape, and a supplement having various formulation forms such as liquid (drink). Such a supplement preparation may be the above-mentioned emulsion composition in the solution state (emulsion state) of the present invention or a drink in which this is dispersed in an aqueous solvent such as water, or the emulsion composition in the solution state (emulsion state) of the present invention. It may be a capsule preparation in which the product is enclosed in a capsule base such as a soft capsule or a hard capsule. Furthermore, even if the emulsion composition in the solution state (emulsion state) of the present invention is spray-dried or freeze-dried, or solidified by adsorbing or supporting it on an excipient, it is also possible to apply this. It may be a tablet, a tablet or pill prepared by compression, or a capsule preparation enclosed in a capsule base.
またコエンザイムQ10含有食品には、コエンザイムQ10含有乳化組成物と任意の成分を組み合わせて調製される機能性食品が含まれる。コエンザイムQ10含有乳化組成物と組み合わせて用いられる成分としては、例えば、各種栄養素、各種ビタミン類(ビタミンA、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンC、ビタミンD、ビタミンE、ビタミンK等)、各種ミネラル類(マグネシウム、亜鉛、鉄、ナトリウム、カリウム、セレン等)、食物繊維、多価不飽和脂肪酸(アラキドン酸、ドコサヘキサエン酸、エイコサペンタエン酸、ドコサペンタエン酸等)、共役脂肪酸類(共役リノール、共役リノレン酸等)、リン脂質(レシチン、リゾレシチン、ホスファチジン酸、ホスファチジルセリン、ホスファチジルエタノールアミン、ホスファチジルグリセロール、ホスファチジルコリン、ホスファチジルイノシトール、ホスファチジルDHA等)、糖脂質類(セレブロシド等)、カロチノイド類(β-カロチン、リコピン、アスタキサンチン、β−クリプトキサンチン等)、フラボノイド類(ケルセチン、ルテオリン、イソフラボン等)、キサントフィル類(カプサンチン、ルテイン、ゼアキサンチン等)、アミノ酸類(グリシン、セリン、アラニン、グルタミン、バリン、ロイシン、イソロイシン、リジン、アルギニン、アスパラギン酸、グルタミン酸、トリプトファン、フェニルアラニン、ヒスチジン、プロリン、メチオニン、システイン等)、その他の栄養素(カルニチン、セサミン、α−リポ酸、イノシトール、D−カイロイノシトール、ピニトール、タウリン、グルコサミン、コンドロイチン硫酸、S−アドノシルメチオニン、クルクミン、γ−オリザノール、グルタチオン、γ−アミノ酪酸、シネフリン、ピロロキノリンキノン、カテキン、カプサイシン等)、分散剤、乳化剤等の安定剤、甘味料、呈味成分(クエン酸、リンゴ酸等)、フレーバー、ローヤルゼリー、プロポリス、アガリクス等から選ばれる1種又は2種以上の成分を挙げることができる。また、ペパーミント、ベルガモット、カモンミール、ラベンダーなどのハーブ類を配合してもよい。また、テアニン、デヒドロエピアンドステロン、メラトニンなどの素材と配合してもよい。ビタミンE、セレン、ホスファチジルイノシトール、アスタキサンチン、β−クリプトキサンチン、ルテイン、ゼアキサンチン、カルニチン、及びα−リポ酸から選ばれる1種又は2種以上の成分を配合することが好ましく、ビタミンE、アスタキサンチン、β−クリプトキサンチン、ルテイン、ゼアキサンチン、カルニチン、及びα−リポ酸から選ばれる1種又は2種以上の成分を配合することがより好ましく、ビタミンE、カルニチン、及びα−リポ酸から選ばれる1種又は2種以上の成分を配合することがさらに好ましく、ビタミンE、及びカルニチンから選ばれる1種又は2種以上の成分を配合することが特に好ましい。Also in the coenzyme Q 10 containing foods include functional foods which are prepared by combining the coenzyme Q 10 containing emulsion composition and optional ingredients. As the component used in combination with coenzyme Q 10 containing emulsion composition, for example, various nutrients, various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.) , Various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), dietary fiber, polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, etc.), conjugated fatty acids (conjugated) Linole, conjugated linolenic acid, etc.), phospholipids (lecithin, lysolecithin, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylcholine, phosphatidylinositol, phosphatidyl DHA, etc.), glycolipids (Cere Broside, etc.), carotenoids (β-carotene, lycopene, astaxanthin, β-cryptoxanthin, etc.), flavonoids (quercetin, luteolin, isoflavone, etc.), xanthophylls (capsanthin, lutein, zeaxanthin, etc.), amino acids (glycine, serine) , Alanine, glutamine, valine, leucine, isoleucine, lysine, arginine, aspartic acid, glutamic acid, tryptophan, phenylalanine, histidine, proline, methionine, cysteine, etc., other nutrients (carnitine, sesamin, α-lipoic acid, inositol, D -Kairinositol, pinitol, taurine, glucosamine, chondroitin sulfate, S-adnosylmethionine, curcumin, γ-oryzanol, glutathione, γ-aminobutyric acid, Furin, pyrroloquinoline quinone, catechin, capsaicin, etc.), dispersants, stabilizers such as emulsifiers, sweeteners, taste ingredients (citric acid, malic acid, etc.), flavors, royal jelly, propolis, agaricus, etc. Two or more components can be mentioned. Moreover, you may mix | blend herbs, such as peppermint, bergamot, camomile meal, and lavender. Moreover, you may mix | blend with raw materials, such as theanine, dehydroepiandosterone, and melatonin. Preferably, one or more components selected from vitamin E, selenium, phosphatidylinositol, astaxanthin, β-cryptoxanthin, lutein, zeaxanthin, carnitine, and α-lipoic acid are added, and vitamin E, astaxanthin, β -More preferably, one or more components selected from cryptoxanthin, lutein, zeaxanthin, carnitine, and α-lipoic acid are blended, and one or more selected from vitamin E, carnitine, and α-lipoic acid It is more preferable to blend two or more components, and it is particularly preferable to blend one or more components selected from vitamin E and carnitine.
これらのサプリメント(食品)や機能性食品の中に配合する本発明のコエンザイムQ10含有乳化組成物の割合は、当該サプリメントを通常量摂取することによって所望のコエンザイムQ10機能を奏すると考えられる量であれば特に制限されない。具体的には、成人1日投与される量のサプリメント中に、コエンザイムQ10が0.01〜5000mg、好ましくは0.1〜2000mgの割合で含まれるように調整することができる。The proportion of these supplements (food) and functional coenzyme Q 10 containing emulsion composition of the present invention to be formulated into foods, the amount that would produce the desired coenzyme Q 10 functions by the usual amounts consumed the supplement If it is, it will not be restrict | limited. More specifically, during the supplement amount administered per day for adults, coenzyme Q 10 is 0.01~5000Mg, preferably it can be adjusted so as to be contained at a rate of 0.1 to 2000 mg.
また本発明が対象とするコエンザイムQ10含有化粧品としては、洗顔化粧料、スキン化粧料(ローション、乳液、クリームなど)、日焼け止め化粧料、メークアップ化粧料(ファンデーション、口紅など)、洗浄化粧料(シャンプー、リンス、ボディーシャンプーなど)、頭皮化粧料(ヘアトニック、へアリキッド、養毛剤など);コエンザイムQ10含有医薬品としては錠剤(コーティング剤で被覆された錠剤を含む)、カプセル剤(硬カプセル剤、軟カプセル剤を含む)、粉末剤、顆粒剤、ドリンク剤、トローチ剤、うがい薬、軟膏、クリーム等を;コエンザイムQ10含有医薬部外品としては歯磨き剤、口中清涼剤、口臭予防剤等を;またコエンザイムQ10含有飼料としてはキャットフードやドッグッフード等の各種ペットフード、観賞魚若しくは養殖魚の餌等を一例として挙げることができるが、これらに制限されるものではない。Also as coenzyme Q 10 containing cosmetics to which the present invention is directed, facial cosmetics, skin cosmetics (lotion, milky lotion, a cream or the like), sunscreen cosmetics, make-up cosmetics (foundation, lipstick, etc.), cleaning cosmetics (shampoo, rinse, and body shampoo), scalp cosmetics (hair tonic, to Arikiddo and tonic); the coenzyme Q 10 containing a medicament (including tablets coated with a coating agent) tablets, capsules (hard capsules , including soft capsules), powders, granules, drinks, lozenges, mouthwashes, ointments, creams and the like; coenzyme Q 10 containing as the quasi-drug dentifrice, mouth fresheners, mouth odor preventive agent the; the various Pettofu such cat food and dog Tsu hood as coenzyme Q 10 containing diet For example, food for aquarium fish, aquarium fish or farmed fish can be mentioned, but the present invention is not limited to these.
本発明のコエンザイムQ10含有乳化組成物は、水に添加し混合した際の溶解性や分散性に優れていることから、好ましくは水を原料として調製されるか、水を含むか、または水溶性である、いわゆる水性の化粧品、医薬品、医薬部外品、または飼料に対して有効に使用することができる。この点から、上記化粧品については、好ましくはスキン化粧料(ローション、乳液、クリームなど)、頭皮化粧料(ヘアトニック、へアリキッド、養毛剤など);医薬品については、好ましくはドリンク剤、うがい薬、軟膏、クリーム、粉末剤、顆粒剤等;医薬部外品としては歯磨き剤、口中清涼剤、口臭予防剤を例示することができる。Coenzyme Q 10 containing emulsion composition of the present invention, since it is excellent in solubility and dispersibility upon addition to water mixture, or preferably is prepared using water as a raw material, or comprises water or water, It can be effectively used for so-called aqueous cosmetics, pharmaceuticals, quasi-drugs, or feed. In this respect, for the above cosmetics, preferably skin cosmetics (lotions, emulsions, creams, etc.), scalp cosmetics (hair tonics, hair liquids, hair nourishing agents, etc.); for pharmaceuticals, preferably drinks, gargles, ointments , Creams, powders, granules, etc .; Examples of quasi-drugs include toothpastes, mouth fresheners, and bad breath prevention agents.
また、本発明のコエンザイムQ10含有乳化組成物は、経口投与した場合の体内吸収性、特にヒトに経口投与した場合の体内吸収性にも優れていることから、経口投与用医薬品に対して有効に使用することができる。この点から医薬品のなかでも経口投与用医薬品を好適なものとして挙げることができる。Moreover, coenzyme Q 10 containing emulsion composition of the present invention, the body absorbent when administered orally, in particular because it is excellent in systemic absorption of when orally administered to a human, effective for oral administration drugs Can be used for From this point, among drugs, drugs for oral administration can be mentioned as suitable.
これらの製品も、食品と同様に、製造の任意の工程で、原料の一つとして上記本発明のコエンザイムQ10含有乳化組成物を配合することによって製造することができる。この工程を除けば、各種製品に関する慣用の製造方法に従って製造することができる。Also these products, like food, can be at any step of the manufacturing, prepared by blending a coenzyme Q 10 containing emulsion composition of the present invention as one of raw materials. If this process is excluded, it can manufacture in accordance with the conventional manufacturing method regarding various products.
上記各種製品の製造にあたり本発明のコエンザイムQ10含有乳化組成物の配合割合は、当該製品を通常量使用することによって所望のコエンザイムQ10機能を奏すると考えられる量であれば特に制限されない。通常、製品100重量%中に含まれるコエンザイムQ10の割合として0.00001〜5重量%の範囲から、製品の種類に応じて適宜設定することができる。中でも医薬品中に配合する本発明のコエンザイムQ10含有乳化組成物の割合としては、具体的には、成人1日投与される量の医薬品中に、コエンザイムQ10が0.01〜5000mg、好ましくは0.1〜2000mgの割合で含まれるように調整することができる。The mixing ratio of various products coenzyme Q 10 containing emulsion composition of the present invention in the production of, not particularly limited as long as it is an amount that would produce the desired coenzyme Q 10 functions by conventional amounts using the product. Usually, the range of 0.00001% by weight as a percentage of Coenzyme Q 10 contained in the product in 100% by weight, can be appropriately set according to the type of product. The proportion of coenzyme Q 10 containing emulsion composition of the present invention inter alia be formulated into pharmaceutical, specifically, in the pharmaceuticals of the amount to be administered per day for adults, coenzyme Q 10 is 0.01~5000Mg, preferably It can adjust so that it may be contained in the ratio of 0.1-2000 mg.
(3)コエンザイムQ10の水可溶性および水分散性の改善・向上方法
本発明はまた脂溶性成分であるコエンザイムQ10の水可溶性および水分散性を改善し、向上するための方法を提供する。(3) Coenzyme Q water-soluble and water-dispersible improvement and enhancement The present invention 10 also improves the water solubility and water-dispersible coenzyme Q 10 is a fat-soluble component, a method for improving.
かかる方法としては、コエンザイムQ10を上記本発明の乳化組成物の形態に調製する方法を挙げることができる。本発明の乳化組成物は水との相溶性が高いため、コエンザイムQ10を、上記本発明の乳化組成物の形態に調製し、その乳化組成物の状態で水に添加配合すると、水に良好に溶解または分散して、光学的に透明(澄明)なコエンザイムQ10を含有する水溶液を得ることが可能になる。なお、制限されないが、この場合のコエンザイムQ10の水への最大溶解性(飽和濃度)としては20重量%程度を例示することができる。Such methods include a method of preparing a coenzyme Q 10 in the form of an emulsion composition of the present invention. Because the emulsified composition of the present invention has a high compatibility with water, coenzyme Q 10, was prepared in the form of an emulsion composition of the present invention, when added to and blended into water in the state of the emulsified composition, excellent in water dissolved or dispersed in, it is possible to obtain an aqueous solution containing an optically transparent (clear) a coenzyme Q 10. Although not limited, the maximum solubility in water of coenzyme Q 10 in this case (saturation concentration) can be exemplified about 20 wt%.
(4)コエンザイムQ10の体内吸収改善・向上方法
さらに本発明は脂溶性成分であるコエンザイムQ10の体内吸収性を改善し、向上するための方法を提供する。(4) Method for Improving and Improving Coenzyme Q 10 in the Body Furthermore, the present invention provides a method for improving and improving the in-vivo absorbability of coenzyme Q 10 which is a fat-soluble component.
かかる方法としては、コエンザイムQ10を上記本発明の乳化組成物の形態に調製する方法を挙げることができる。本発明の乳化組成物は、生体への吸収性、特に経口投与に対する吸収性が高いため、コエンザイムQ10を、上記本発明の乳化組成物の形態に調製し、その乳化組成物の状態または乳化組成物を含む状態で経口摂取または投与すると、高い体内吸収性が得られ、コエンザイムQ10の機能(作用効果)をより有効に享受することができる。Such methods include a method of preparing a coenzyme Q 10 in the form of an emulsion composition of the present invention. Emulsion composition of the present invention, absorption into a living body, particularly because of high absorption on oral administration, coenzyme Q 10, was prepared in the form of an emulsion composition of the present invention, the state or emulsion of the emulsified composition When ingested or administered in comprising the composition, high systemic absorption property is obtained, it is possible to receive functions of coenzyme Q 10 (the operational effect) more effectively.
(5)コエンザイムQ10の体内抗酸化能向上方法、及び抗酸化剤
さらに本発明はコエンザイムQ10の体内抗酸化能を向上するための方法を提供する。(5) Coenzyme Q 10 in vivo antioxidant capacity improving method and antioxidant Further, the present invention provides a method for improving coenzyme Q 10 in vivo antioxidant capacity.
かかる方法としては、コエンザイムQ10を上記本発明の乳化組成物の形態に調製する方法を挙げることができる。本発明の乳化組成物は、生体への吸収性、特に経口投与に対する吸収性が高いため、コエンザイムQ10を、上記本発明の乳化組成物の形態に調製し、その乳化組成物の状態または乳化組成物を含む状態で経口摂取または投与すると、より高い体内抗酸化能を発揮することができ、コエンザイムQ10の抗酸化機能(作用効果)をより有効に享受することができる。Such methods include a method of preparing a coenzyme Q 10 in the form of an emulsion composition of the present invention. Emulsion composition of the present invention, absorption into a living body, particularly because of high absorption on oral administration, coenzyme Q 10, was prepared in the form of an emulsion composition of the present invention, the state or emulsion of the emulsified composition When ingested or administered in comprising the composition, can exhibit a higher body antioxidant activity, it is possible to receive the anti-oxidation function of coenzyme Q 10 (the operational effect) more effectively.
このため、本発明の乳化組成物は抗酸化剤として使用することもできる。好ましくは生体に対する抗酸化剤としての使用である。よって本発明は、前述する本発明の乳化組成物を有効成分とする抗酸化剤、好ましくは生体に対する抗酸化剤を提供するものである。生体における酸化作用を防止するという点から、老化の予防、癌の予防、動脈硬化、糖尿病、アレルギー、リュウマチ性疾患、エイズ、パーキンソン病、アルツハイマー型痴呆症、糖尿病性網膜症、白内障、心筋疾患、脳梗塞、高血圧、胃潰瘍、虚血性腸炎、慢性膵炎、腎不全等の予防に有効に利用することができる。 For this reason, the emulsion composition of this invention can also be used as an antioxidant. Preferably, it is used as an antioxidant for living bodies. Therefore, the present invention provides an antioxidant, preferably an antioxidant for a living body, comprising the above-described emulsion composition of the present invention as an active ingredient. In terms of preventing oxidative action in the living body, prevention of aging, prevention of cancer, arteriosclerosis, diabetes, allergy, rheumatic diseases, AIDS, Parkinson's disease, Alzheimer's dementia, diabetic retinopathy, cataract, myocardial disease, It can be effectively used for prevention of cerebral infarction, hypertension, gastric ulcer, ischemic enteritis, chronic pancreatitis, renal failure and the like.
なお、体内抗酸化能茶の評価は、通常、血清抗酸化力を測定することにより行うことができる。例えば、血清の抗酸化力の測定は、血清中の抗酸化物質が活性酸素・フリーラジカルに電子を与え、酸化反応を止める還元能力を計測することによって行うことができる。具体的には市販の試験キッット(例えばウイスマー研究所社製のBAP Testなど)を用いることによって簡便に測定することができ、また外部機関(例えば、千代田パラメディカルケアセンター等)に測定を依頼することによっても行うことができる。 In addition, evaluation of the body antioxidant ability tea can be normally performed by measuring serum antioxidant power. For example, the antioxidant power of serum can be measured by measuring the reducing ability of antioxidant substances in serum to give electrons to active oxygen / free radicals and stop the oxidation reaction. Specifically, it can be easily measured by using a commercially available test kit (for example, BAP Test manufactured by Wismer Laboratories Inc.), or request measurement from an external organization (for example, Chiyoda Paramedical Care Center). Can also be done.
以下に、本発明の構成ならびに効果をより明確にするために、実験例および実施例を記載する。但し、本発明は、これらの実験例等に何ら制限されるものではない。
実験例1 中鎖トリグリセライドの添加効果
表1に示す処方および下記の方法に従って、本発明に係るコエンザイムQ10含有乳化組成物を調製した。なお、中鎖トリグリセライドとして、カプリル酸/カプロン酸混合トリグリセライド(商品名:ODO、日清オイリオ(株)製)を使用した。In order to clarify the structure and effects of the present invention, experimental examples and examples are described below. However, the present invention is not limited to these experimental examples.
According to the formulation and the following methods are shown in addition effect Table 1 of Example 1 in the chain triglyceride, coenzyme Q 10 containing emulsion composition according to the present invention was prepared. In addition, caprylic acid / caproic acid mixed triglyceride (trade name: ODO, manufactured by Nisshin Oilio Co., Ltd.) was used as the medium chain triglyceride.
<調製方法>
コエンザイムQ10、中鎖トリグリセライド(但し、比較例1では無添加、比較例3では中鎖トリグリセライドに代えてサフラワー油(パルミチン酸、ステアリン酸、オレイン酸及びリノール酸を主構成脂肪酸とするトリグリセライド)、及びデカグリセリンモノステアリン脂肪酸エステル(HLB15)の混合物を100℃に加熱し溶解し、この溶解液を、常温下にあるグリセリンに添加し、液温40℃でポリトロン(PolytoronPT-3000、KINEMATICA AG製)で回転数15,000rpm、10分間混合し、これに更に水を添加、混合してコエンザイムQ10含有乳化組成物を得た。<Preparation method>
Coenzyme Q 10 , medium chain triglyceride (but not added in Comparative Example 1, safflower oil in Comparative Example 3 instead of medium chain triglyceride (triglyceride containing palmitic acid, stearic acid, oleic acid and linoleic acid as main constituent fatty acid) , And a mixture of decaglycerin monostearate fatty acid ester (HLB15) heated to 100 ° C. and dissolved, this solution was added to glycerin at room temperature, and polytron (Polytoron PT-3000, manufactured by KINEMATICA AG) at a solution temperature of 40 ° C. rpm 15,000rpm in), and mixed for 10 minutes, further adding water thereto and mixed to obtain a coenzyme Q 10 containing emulsion composition.
<水への溶解性・分散性の評価>
上記で調製したコエンザイムQ10含有乳化組成物(実施例1〜3、比較例1〜3)1gを、イオン交換水100mlに添加してコエンザイムQ10含有水溶液を調製した。コエンザイムQ10の水への可溶性または分散性を評価するために、当該水溶液中の720nmに於ける吸光度を測定し、透明度を比較した。結果を表2に示す。吸光度が小さいほど水溶液の透明度が高い(水への溶解性・分散性が高い)ことを示す。<Evaluation of solubility and dispersibility in water>
Coenzyme Q 10 containing emulsion composition prepared in the above (Examples 1 to 3, Comparative Examples 1 to 3) and 1g, to prepare a coenzyme Q 10 containing aqueous solution was added to ion-exchanged water 100 ml. To evaluate the solubility or dispersibility in water of coenzyme Q 10, the in absorbance measured 720nm in the aqueous solution, were compared transparency. The results are shown in Table 2. The smaller the absorbance, the higher the transparency of the aqueous solution (the higher the solubility and dispersibility in water).
本結果より明らかなように、中鎖トリグリセライドのコエンザイムQ10に対する配合比率に応じて乳化組成物の水への溶解・分散性(水溶液の透明性)が異なることがわかった。コエンザイムQ1010重量部に対して、中鎖トリグリセライドを1〜10重量部の割合で配合した乳化組成物(実施例1〜3)は、水への溶解・分散性が高く、高い透明性を有していた。また、油脂として中鎖トリグリセライドに代えてサフラワー油を実施例2と同等量配合した比較例3の結果から、使用する油脂の種類によって水に対する溶解・分散性(水溶液の透明性)が異なることが判明した。これらの結果から、水に対する溶解性または分散性の点から、油脂として中鎖トリグリセライドが最適であり、これをコエンザイムQ1010重量部に対して1〜10重量部の割合で用いることが好ましいことがわかった。As apparent from the results, dissolution and dispersibility in water of the emulsion composition according to the formulation ratio of coenzyme Q 10 of the medium-chain triglyceride (transparency of the aqueous solution) was found to be different. The emulsified composition (Examples 1 to 3) containing 1 to 10 parts by weight of medium chain triglyceride with respect to 10 parts by weight of Coenzyme Q 10 has high solubility and dispersibility in water and high transparency. Had. Moreover, from the result of Comparative Example 3 in which safflower oil was blended in the same amount as in Example 2 instead of medium chain triglyceride as fat, the solubility / dispersibility in water (transparency of aqueous solution) differs depending on the type of fat used. There was found. From these results, from the viewpoint of solubility or dispersibility in water, medium-chain triglycerides are optimal as fats and oils, and it is preferable to use them at a ratio of 1 to 10 parts by weight with respect to 10 parts by weight of Coenzyme Q 10. I understood.
実験例2
表3に示す処方および下記の方法に従って、本発明に係るコエンザイムQ10含有乳化組成物を調製した。なお、中鎖トリグリセライドとして、カプリル酸/カプロン酸混合トリグリセライド(商品名:ODO、日清オイリオ(株)製)を使用した。また本実験では、リン脂質の例として、酵素分解レシチンを、HLB10以上のグリセリン脂肪酸エステルの例としてデカグリセリンモノステアリン酸エステル(HLB15)を用いた。 Experimental example 2
According to the formulation and methods described below are shown in Table 3, the coenzyme Q 10 containing emulsion composition according to the present invention was prepared. In addition, caprylic acid / caproic acid mixed triglyceride (trade name: ODO, manufactured by Nisshin Oilio Co., Ltd.) was used as the medium chain triglyceride. In this experiment, enzymatically degraded lecithin was used as an example of phospholipid, and decaglycerol monostearate (HLB15) was used as an example of glycerol fatty acid ester of HLB10 or higher.
<調製方法>
コエンザイムQ10、中鎖トリグリセライド(但し、比較例4および5は無添加)、デカグリセリンモノステアリン脂肪酸エステル(HLB15)、及び酵素分解レシチン(但し、比較例4は無添加)の混合物を100℃に加熱し溶解し、この溶解液を、常温下にあるグリセリンに添加し、液温40℃でポリトロン(PolytoronPT-3000、KINEMATICA AG製)で回転数15,000rpm、10分間混合した。これに更に水を添加して、混合してコエンザイムQ10含有乳化組成物を得た。<Preparation method>
A mixture of coenzyme Q 10 , medium chain triglyceride (without addition of Comparative Examples 4 and 5), decaglycerin monostearic acid fatty acid ester (HLB15), and enzymatically decomposed lecithin (but without addition of Comparative Example 4) at 100 ° C. This was dissolved by heating, and this dissolved solution was added to glycerin at room temperature, and mixed at a liquid temperature of 40 ° C. with a Polytron (Polytoron PT-3000, manufactured by KINEMATICA AG) at a rotation speed of 15,000 rpm for 10 minutes. To this was further added water and mixed to obtain a coenzyme Q 10 containing emulsion composition.
<水への溶解性・分散性、保存安定性の評価>
上記で得られた各コエンザイムQ10含有乳化組成物1gを、直ちにイオン交換水100mlに添加し、コエンザイムQ10含有水溶液を調製した。次いで、コエンザイムQ10の水への可溶性または分散性を評価するために、当該水溶液中の720nmに於ける吸光度を測定し、透明度を比較した。<Evaluation of solubility / dispersibility in water and storage stability>
Each Coenzyme Q 10 containing emulsion composition 1g obtained above, was added immediately to the ion exchanged water 100 ml, to prepare a coenzyme Q 10 containing aqueous solution. Then, in order to evaluate the solubility or dispersibility in water of coenzyme Q 10, the in absorbance measured 720nm in the aqueous solution, were compared transparency.
また、コエンザイムQ10含有乳化組成物を、60℃で3日間保存した後、上記と同様に保存後の乳化組成物 1gをイオン交換水100mlに添加してコエンザイムQ10含有水溶液を調製し、720nmに於ける吸光度を測定した。Moreover, coenzyme Q10-containing emulsion composition, after storage for 3 days at 60 ° C., and the and the emulsified composition 1g after storage in the same manner were added to ion-exchanged water 100ml was prepared coenzyme Q 10 containing aqueous solution, the 720nm The absorbance was measured.
結果を表4に示す。吸光度が小さいほど水溶液の透明度が高く、水に対する溶解性・分散性が高いことを示す。また、調製直後の乳化組成物を用いた水溶液の吸光度(調製直後の吸光度)と保存後の乳化組成物を用いた水溶液の吸光度(保存後の吸光度)との差が小さいほど、乳化組成物が保存安定性に優れていることを示す。 The results are shown in Table 4. The smaller the absorbance, the higher the transparency of the aqueous solution and the higher the solubility / dispersibility in water. Further, the smaller the difference between the absorbance of the aqueous solution using the emulsified composition immediately after preparation (absorbance immediately after preparation) and the absorbance of the aqueous solution using the emulsion composition after storage (absorbance after storage), the more the emulsion composition becomes. It shows excellent storage stability.
上記の結果から、コエンザイムQ10、中鎖トリグリセライド、多価アルコール、水および界面活性剤(グリセリン脂肪酸エステルとリン脂質)を添加することによって(実施例4、5)、調製直後の乳化組成物だけでなく、これを60℃で3日間保存した後の乳化組成物も、水に対する溶解・分散性に優れており、透明度の高い水溶液が調製できることが明らかとなった。このことから、本発明の乳化組成物は、高い保存安定性を備えていることが確認された。From the above results, by adding coenzyme Q 10 , medium chain triglyceride, polyhydric alcohol, water and surfactant (glycerin fatty acid ester and phospholipid) (Examples 4 and 5), only the emulsified composition immediately after preparation In addition, it was revealed that the emulsion composition after storage at 60 ° C. for 3 days was also excellent in solubility and dispersibility in water, and an aqueous solution with high transparency could be prepared. From this, it was confirmed that the emulsion composition of the present invention has high storage stability.
実験例3 動物を利用した生体吸収性の比較
表5に示す処方及び下記の記載に従い、本発明に係るコエンザイムQ10含有乳化組成物を調製した。中鎖トリグリセライドとして、カプリル酸/カプロン酸混合トリグリセライド(商品名:ココナードMT、花王(株)製)を使用した。また本実験では、リン脂質の例として、酵素分解レシチンを、HLB10以上のグリセリン脂肪酸エステルの例としてデカグリセリンモノオレイン酸エステル(HLB12)を用いた。According to the formulation and the following description are shown in bioabsorbable comparison table 5 using Experimental Example 3 animals, coenzyme Q 10 containing emulsion composition according to the present invention was prepared. A caprylic acid / caproic acid mixed triglyceride (trade name: Coconut MT, manufactured by Kao Corporation) was used as the medium chain triglyceride. In this experiment, enzymatically degraded lecithin was used as an example of phospholipid, and decaglycerol monooleate (HLB12) was used as an example of glycerol fatty acid ester of HLB10 or higher.
<調製方法>
コエンザイムQ10、中鎖トリグリセライド、デカグリセリンモノオレイン酸エステル(HLB12)、酵素分解レシチン、抽出トコフェロールを水に加え100℃で加熱溶解した。これを常温下のグリセリンに添加し、品温40℃でPolytoronPT-3000(KINEMATICA AG製)で15,000rpm、10分間混合し、更に水を添加し混合した。次いで高圧ホモジナイザーを用いて、48Mpa(490Kgf/cm2)で均一処理を行い、乳化組成物を得た。この乳化組成物の平均粒子径(動的光散乱法による重量平均粒子径)を、光散乱光度計DLS-7000(大塚電子製)を用いて測定したところ、それぞれ55nm(実施例6)、42nm(比較例6)であった。<Preparation method>
Coenzyme Q 10 , medium chain triglyceride, decaglycerin monooleate (HLB12), enzymatically decomposed lecithin and extracted tocopherol were added to water and dissolved by heating at 100 ° C. This was added to glycerin at room temperature, mixed at 15,000 rpm for 10 minutes with Polytoron PT-3000 (manufactured by KINEMATICA AG) at a product temperature of 40 ° C., and further mixed with water. Next, using a high-pressure homogenizer, uniform treatment was performed at 48 Mpa (490 kgf / cm 2 ) to obtain an emulsified composition. When the average particle size (weight average particle size by dynamic light scattering method) of this emulsified composition was measured using a light scattering photometer DLS-7000 (manufactured by Otsuka Electronics Co., Ltd.), it was 55 nm (Example 6) and 42 nm, respectively. (Comparative Example 6).
この乳化組成物(実施例6および比較例6)を、それぞれ下記の条件に従ってラット(Slc:SD、雄性、7週齢、n=3)に経口投与し、経時的にコエンザイムQ10の血中濃度を測定して、コエンザイムQ10の体内吸収性を評価した。なお、投与には、予め15〜20時間絶食させておいたラットを使用した。The emulsion composition (Example 6 and Comparative Example 6), rats respectively according to the conditions of the following (Slc: SD, male, 7 weeks old, n = 3) in oral administration, blood over time the coenzyme Q 10 by measuring the concentration, it was evaluated in the body absorption of coenzyme Q 10. For administration, rats that had been fasted for 15 to 20 hours in advance were used.
具体的には、各乳化組成物(実施例6および比較例6)を注射用水で10倍に希釈して、コエンザイムQ10として100mg/kgの投与量で、ラットに強制的に経口投与した。投与後1時間、3時間、および6時間の時点で、各々ラットを屠殺して血液を採取し、採血した血液から定法により血清を調製した。血清は測定開始まで−40℃で保管した。血清中のコエンザイムQ10含量の測定は、血清からn-へキサンでコエンザイムQ10を抽出し、抽出液中のコエンザイムQ10含量(ng/ml)をLC−MS法にて分析した。結果を表6及び図1に示す。Specifically, by diluting 10-fold the emulsion composition (Example 6 and Comparative Example 6) in water for injection at a dose of 100 mg / kg as a coenzyme Q 10, was forcibly administered orally to rats. At 1 hour, 3 hours, and 6 hours after administration, rats were sacrificed and blood was collected, and serum was prepared from the collected blood by a conventional method. Serum was stored at −40 ° C. until the start of measurement. Measurements of coenzyme Q 10 content in serum from the serum to the n- extracting coenzyme Q 10 in hexane, coenzyme Q 10 content in the extract (ng / ml) was analyzed by LC-MS method. The results are shown in Table 6 and FIG.
<測定結果> <Measurement results>
実施例6と比較例6を比較すると、中鎖グリセライドを含有していない比較例6の乳化組成物に比べ、中鎖グリセライドを含有する実施例6の乳化組成物では、投与後早い段階からコエンザイムQ10が体内に吸収されており、摂取後短時間で高い吸収性を発揮する傾向が認められた。When Example 6 and Comparative Example 6 were compared, the emulsion composition of Example 6 containing medium chain glyceride compared to the emulsion composition of Comparative Example 6 not containing medium chain glyceride, and coenzyme from an early stage after administration. Q 10 has been absorbed into the body, they tend to exhibit a high absorption in a short period of time after the intake was observed.
一般に乳化組成物の吸収性をよくするために粒子径を小さくするという方法が用いられる。これに対して、本発明の実施例6の乳化組成物は比較例6の乳化組成物よりも粒子径が大きいにもかかわらず、生体への吸収性が優れていた。その理由は明らかではないが、中鎖トリグリセライドを含むことによるところが大きいと考えられる。 In general, a method of reducing the particle size is used to improve the absorbability of the emulsion composition. On the other hand, the emulsion composition of Example 6 of the present invention was superior in absorbability to the living body despite the larger particle size than the emulsion composition of Comparative Example 6. The reason for this is not clear, but it is thought to be largely due to the inclusion of medium chain triglycerides.
実験例4 ヒトを利用した生体吸収性の比較(CoQ10含有乳化組成物含有飲料のヒト吸収試験)
(1)被験試料の調製
(1-1)CoQ10含有乳化組成物含有飲料
コエンザイムQ10含有乳化組成物を上記実施例6に従って調製し、これを精製水で希釈し、コエンザイムQ10を30mg含有する飲料(試験食品1)、および60mg含有する飲料(試験食品2)を調製した。 Experimental Example 4 Comparison of Bioabsorbability Utilizing Human (Human Absorption Test of Beverage Containing CoQ 10 Containing Emulsion Composition)
(1) Preparation of test sample
(1-1) CoQ 10- containing emulsion composition-containing beverage Coenzyme Q 10- containing emulsion composition was prepared according to Example 6 above, diluted with purified water, and a beverage containing 30 mg of Coenzyme Q 10 (test food 1) And a beverage (test food 2) containing 60 mg.
(1-2)CoQ10含有ソフトカプセル
コエンザイムQ10 200gをオリーブオイル400gに添加して、約60℃で溶解、均一に撹拌した後に冷却し、コエンザイムQ10含有素材を得た。ゼラチン70重量%及びグリセリン30重量%を混和、膨潤させ、溶解ゼラチンシートを作成した。このゼラチンシートに内溶液として上記コエンザイムQ10含有素材を1カプセルあたり300mgの内容量になるように充填し、乾燥させ、1カプセルあたりコエンザイムQ10を100mg含有するソフトカプセル(試験食品3)を得た。(1-2) CoQ 10- containing soft capsule 200 g of Coenzyme Q 10 was added to 400 g of olive oil, dissolved at about 60 ° C., stirred uniformly, and then cooled to obtain a Coenzyme Q 10- containing material. Gelatin 70% by weight and glycerin 30% by weight were mixed and swollen to prepare a dissolved gelatin sheet. This as an internal solution in gelatin sheets filled with the Coenzyme Q 10 containing material such that the contents of 300mg per capsule, dried, and 1 capsule per Coenzyme Q 10 was obtained soft capsules (test food 3) containing 100mg .
(1-3)CoQ10非含有飲料
上記実施例6(表5)の乳化組成物の処方において、コエンザイムQ10 を配合せず、その分水を10g増したコエンザイムQ10非含有乳化組成物を調製し、これを希釈してコエンザイムQ10非含有飲料(試験食品4)を調製した。In the formulation of the emulsion composition of (1-3) CoQ 10 free beverages above Example 6 (Table 5), was not added coenzyme Q 10, coenzyme Q 10 free emulsion composition the diversion increased 10g prepared was prepared was diluted coenzyme Q 10 free beverages (test food 4) this.
(2)ヒト吸収試験
上記試験試料1〜4をヒトに摂取させて、血中のコエンザイムQ10濃度の推移からコエンザイムQ10の吸収性を評価した。なお試験は、健康診断データから基準に適合する登録ボランティア(被験者24名、男性)を対象として行った。これらの被験者に対して、ヘルシンキ宣言に基づいて、試験担当医が事前に試験について十分な説明を行い、被験者の自発的な協力同意(インフォームドコンセント)を得て試験参加への同意書に記名してもらった。(2) Human absorption test
The test sample 1-4 by ingested by humans, to evaluate the absorbability of coenzyme Q 10 from a change of the coenzyme Q 10 concentration in the blood. The test was conducted on registered volunteers (24 subjects, men) who met the criteria from the health check data. Based on the Declaration of Helsinki, the investigator will fully explain the study in advance and obtain the subject's voluntary cooperation (informed consent) and register it in the consent form for participation in the study. I was asked to.
被験者(24名)は、上記調製法にて調製した試験食品1(CoQ1030mg含有飲料)摂取群(A群)、被験食品2(CoQ1060mg含有飲料)摂取群(B群)、試験食品3(CoQ10100mg含有カプセル)摂取群(C群)、及び試験食品4(CoQ10非含有飲料)摂取群(D群)の4群(各6名)にわけた。The subjects (24) were the test food 1 (CoQ 10 30 mg-containing beverage) intake group (Group A), the test food 2 (CoQ 10 60 mg-containing beverage) intake group (Group B), the test food prepared by the above preparation method. 3 groups (CoQ 10 100 mg-containing capsule) intake group (Group C) and test food 4 (CoQ 10 non-containing beverage) intake group (Group D) were divided into 4 groups (6 persons each).
朝食は各被験者共通とし、朝食を取った直後(午前9時)に各試験食品を摂取してもらった。採血を、試験食品摂取前、並びに試験食品摂取から2、4、6、8、10、12時間後(午前9時、午前11時、午後1時、午後3時、午後5時、午後7時)、及び24時間後(翌日の午前9時)の合計7回実施した。採った血は、採血後即時に血清分離し、血清を−30℃にて凍結保存した。 Breakfast was common to all subjects and each test food was ingested immediately after breakfast (9:00 am). Blood sampling should be done before taking the test food and 2, 4, 6, 8, 10, 12 hours after taking the test food (9 am, 11 am, 1 pm, 3 pm, 5 pm, 7 pm ), And 24 hours later (9 am the next day), a total of 7 times. The collected blood was subjected to serum separation immediately after blood collection, and the serum was stored frozen at -30 ° C.
A〜D群の被験者から採血した血清を用いて、血清コエンザイムQ10濃度、及び血清抗酸化力(BAP)を測定した。なお、血清コエンザイムQ10濃度の測定は日研ザイル株式会社、血清抗酸化能の測定(銅イオンに対する還元力測定)は千代田パラメディカルケアセンターに依頼して実施した。Using sera were bled A~D group subjects, serum coenzyme Q 10 concentration, and serum antioxidant force (BAP) was measured. The measurement of serum coenzyme Q 10 concentration Nikken rope Co., measurement of serum antioxidant capacity (reducing power measurements for copper ions) were performed by requesting the Chiyoda paramedic care center.
血清コエンザイムQ10濃度の測定結果を図2に、血清抗酸化力の測定結果を図3に示す。なお、試験結果は被験者の平均値で示す。各群間比較にはt検定を用い、両側有意確率5%以下(p<0.05)を有意差ありとし、10%以下(p<0.1)の場合については傾向があるとした。The measurement results of serum coenzyme Q 10 concentration in FIG. 2 shows the results of measurement of serum antioxidant capacity in FIG. In addition, a test result is shown by a test subject's average value. A t-test was used for comparison between the groups, and a two-sided significance probability of 5% or less (p <0.05) was considered significant, and a case of 10% or less (p <0.1) was considered to have a tendency.
図2が示す通り、試験食品4(CoQ10非含有飲料)を摂取した被験者(D群)については、血清コエンザイムQ10濃度は全く変化しなかった。コエンザイムQ10を含有する試験食品1〜3を摂取した被験者(A〜C群)については、血清中のコエンザイムQ10濃度は、試験食品摂取後約6時間でピークとなった。血清コエンザイムQ10濃度から評価して、コエンザイムQ10の吸収率が高い試験食品は、順に、コエンザイムQ10を60mg含有する飲料(試験食品1)、コエンザイムQ10を30mg含有する飲料(試験食品2)、およびコエンザイムQ10を100mg含有するソフトカプセル(試験食品3)であり、本発明コエンザイムQ10含有飲料の吸収率が極めて良好であることが判明した。As shown in FIG. 2, for the
また図3が示す通り、血清抗酸化力は、コエンザイムQ10含有飲料(試験食品1及び2)を摂取した群(A及びB群)では摂取後8時間でピークとなった。コエンザイムQ10を60mg含有した飲料を摂取した群は摂取前と比較して優位差が認められ、コエンザイムQ10を60mg含有した飲料が血清抗酸化力を向上させることが判明した。As also shown in FIG. 3, serum antioxidant capacity was peaked coenzyme Q 10 containing beverage (
実施例7 コエンザイムQ10含有食品(清涼飲料水)
コエンザイムQ10含有食品として、下記の処方に従ってコエンザイムQ10含有清涼飲料水を調製した。なお、ここではコエンザイムQ10含有乳化組成物として上記実施例2で調製した乳化組成物を使用したが、実施例1〜6のいずれをも使用することができる。 Example 7 Coenzyme Q 10- containing food (soft drink)
As Coenzyme Q 10-containing foods, to prepare a coenzyme Q 10 containing soft drink in accordance with the following recipe. Here, although using the emulsion composition prepared in Example 2 as a coenzyme Q 10 containing emulsion composition, it can be used any of Examples 1-6.
<調製方法>
砂糖、クエン酸、クエン酸三ナトリウムを水に溶解した後、コエンザイムQ10含有乳化組成物、グレープフルーツフレーバーを添加した。本飲料を120ml褐色ガラス瓶容器に100mlずつ充填し、キャッピングを行った。さらに、水浴中で内温 70℃で20分間殺菌した後、水冷し、コエンザイムQ10を100mg/120gの割合で含有した清涼飲料水を得た。<Preparation method>
After dissolving sugar, citric acid, trisodium citrate in water, coenzyme Q 10 containing emulsion composition was added grapefruit flavors. 100 ml of this beverage was filled into 120 ml brown glass bottle containers and capped. Furthermore, after sterilization at an internal temperature of 70 ° C. 20 min in a water bath, and cooled with water to obtain a soft drink containing a coenzyme Q 10 at a ratio of 100 mg / 120 g.
実施例8 コエンザイムQ10含有食品(ゼリー)
コエンザイムQ10含有食品として、下記の処方に従ってコエンザイムQ10含有ゼリーを調製した(下記処方中、*は三栄源エフ・エフ・アイ(株)製の商品を意味する)。なお、ここではコエンザイムQ10含有乳化組成物として上記実施例2で調製した乳化組成物を使用したが、実施例1〜6のいずれをも使用することができる。 Example 8 Coenzyme Q 10- containing food (jelly)
Coenzyme Q 10 as containing foods, to prepare a coenzyme Q 10 containing jelly according to the formulation of the following (in the following formulation, * means the products manufactured by San-Ei Gen FFI Co., Ltd.). Here, although using the emulsion composition prepared in Example 2 as a coenzyme Q 10 containing emulsion composition, it can be used any of Examples 1-6.
<調製方法>
水を攪拌しながら、砂糖、粉末水飴、ゲルアップWM-100の粉体混合物を添加し、80℃で10分間加熱溶解する。さらに、果汁、クエン酸、ブランデー、カロチンベース、コエンザイムQ10含有乳化組成物を添加する。次いで、香料を添加し、均一に混合する。ゼリーカップに充填し、キャッピング後、内温85℃で30分間殺菌する。水浴中で室温まで冷却し、固化させ、コエンザイムQ10を 50mg/100gの割合で含有するゼリーを得た。<Preparation method>
While stirring water, add a powder mixture of sugar, powdered syrup, and gel-up WM-100, and dissolve by heating at 80 ° C. for 10 minutes. Moreover, it added fruit juice, citric acid, brandy, carotene base, coenzyme Q 10 containing emulsion composition. The fragrance is then added and mixed uniformly. Fill the jelly cup, capping and sterilize at an internal temperature of 85 ° C for 30 minutes. It was cooled to room temperature in a water bath to solidify to obtain a jelly containing coenzyme Q 10 at a ratio of 50 mg / 100 g.
実施例9 錠剤
下記の処方に従ってコエンザイムQ10含有錠剤を調製した。なお、ここではコエンザイムQ10含有乳化組成物として上記実施例2で調製した乳化組成物を使用した。但し、実施例1〜6のいずれをも使用することができる。 It was prepared coenzyme Q 10 containing tablets according to the formulation of Example 9 Tablets below. Here, using the emulsion composition prepared in Example 2 as a coenzyme Q 10 containing emulsion composition. However, any of Examples 1 to 6 can be used.
<製法>
成分1〜4に水を適量加えてよく混練し、押出し造粒機にて造粒後、乾燥して顆粒を得る。次いで成分5を加えてよく混和したのち打錠(300mg/錠)成形し錠剤を得た。当該錠剤中を1日3回3錠ずつ摂取することで、補酵素Q10(ユビキノン)を27mg/日摂取できる。 <Production method>
An appropriate amount of water is added to
実施例19 クリーム
下記の処方に従ってコエンザイムQ10含有クリームを調製した。なお、ここではコエンザイムQ10含有乳化組成物として上記実施例2で調製した乳化組成物を使用したが、実施例1〜6のいずれをも使用することができる。
It was prepared coenzyme Q 10 containing cream according to the formulation of Example 19 Cream below. Here, although using the emulsion composition prepared in Example 2 as a coenzyme Q 10 containing emulsion composition, it can be used any of Examples 1-6.
<製法>
ステアリン酸を70〜80℃に加熱溶解し、別途水酸化カリウム及びグリセリンを水に加え、同温になるまで加熱する。撹拌しながら両方の溶解液を混合し、次いでコエンザイムQ10含有乳化組成物を加え混合した後に徐々に冷却し、コエンザイムQ10含有クリームを得た。<Production method>
Stearic acid is dissolved by heating at 70 to 80 ° C., and potassium hydroxide and glycerin are separately added to water and heated to the same temperature. Stirring and mixing both solution while, then slowly cooled after mixing added coenzyme Q 10 containing emulsion composition, to give a coenzyme Q 10 containing cream.
Claims (28)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006537821A JP5147239B2 (en) | 2004-09-29 | 2005-09-29 | Coenzyme Q10-containing emulsion composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004284333 | 2004-09-29 | ||
JP2004284333 | 2004-09-29 | ||
JP2006537821A JP5147239B2 (en) | 2004-09-29 | 2005-09-29 | Coenzyme Q10-containing emulsion composition |
PCT/JP2005/018016 WO2006035900A1 (en) | 2004-09-29 | 2005-09-29 | Coenzyme q10-containing emulsified composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006035900A1 true JPWO2006035900A1 (en) | 2008-05-15 |
JP5147239B2 JP5147239B2 (en) | 2013-02-20 |
Family
ID=36119046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006537821A Active JP5147239B2 (en) | 2004-09-29 | 2005-09-29 | Coenzyme Q10-containing emulsion composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5147239B2 (en) |
WO (1) | WO2006035900A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4703388B2 (en) * | 2005-12-06 | 2011-06-15 | 植田製油株式会社 | Thioctic acid composition and method for producing the same |
JP5286086B2 (en) * | 2006-09-08 | 2013-09-11 | 株式会社カネカ | Composition containing reduced coenzyme Q10 and lysolecithin |
US20080145411A1 (en) * | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
JP2008092806A (en) * | 2006-10-06 | 2008-04-24 | Sanei Gen Ffi Inc | Method for producing turmeric-containing beverage |
JP2008143841A (en) * | 2006-12-11 | 2008-06-26 | Taiyo Kagaku Co Ltd | Composition containing highly crystalline substance |
JP2008239580A (en) * | 2007-03-28 | 2008-10-09 | Fujifilm Corp | Emulsion composition, and food and cosmetic containing the same |
KR100849537B1 (en) * | 2007-07-04 | 2008-07-31 | 유효경 | Nano-emulsion composition of coenzyme q10 |
WO2009025372A1 (en) * | 2007-08-23 | 2009-02-26 | Kaneka Corporation | Composition containing reduced coenzyme q10, and method for stabilizing the composition |
WO2009044858A1 (en) * | 2007-10-03 | 2009-04-09 | The Nisshin Oillio Group, Ltd. | Edible oil-and-fat composition |
JP4501035B2 (en) * | 2007-10-03 | 2010-07-14 | 日清オイリオグループ株式会社 | Edible oil and fat composition |
WO2009044859A1 (en) * | 2007-10-03 | 2009-04-09 | The Nisshin Oillio Group, Ltd. | Edible oil-and-fat composition |
JP2009100736A (en) * | 2007-10-03 | 2009-05-14 | Nisshin Oillio Group Ltd | Edible oil-and-fat composition |
JP2009100735A (en) * | 2007-10-03 | 2009-05-14 | Nisshin Oillio Group Ltd | Edible oil-and-fat composition |
WO2009044860A1 (en) * | 2007-10-03 | 2009-04-09 | The Nisshin Oillio Group, Ltd. | Edible oil-and-fat composition |
WO2009078245A1 (en) * | 2007-12-19 | 2009-06-25 | Foodtech Trading Co., Ltd. | Transparent emulsified composition and cosmetic and food containing the same |
JP2009149542A (en) * | 2007-12-19 | 2009-07-09 | Foodtech Trading Co Ltd | Transparent emulsion composition, and cosmetics and foodstuffs containing it |
JP5820256B2 (en) * | 2011-02-10 | 2015-11-24 | 株式会社ファンケル | Self-emulsifying formulation |
JP5706349B2 (en) * | 2012-02-01 | 2015-04-22 | 株式会社ファンケル | Stable composition with high concentration of coenzyme Q10 |
JP5727974B2 (en) * | 2012-07-13 | 2015-06-03 | 太陽化学株式会社 | Composition containing highly crystalline substance |
TWI465233B (en) * | 2013-04-12 | 2014-12-21 | Tci Co Ltd | A compound containing coenzyme q10 and the producing method thereof |
JP6459206B2 (en) * | 2014-04-25 | 2019-01-30 | ユーハ味覚糖株式会社 | Superabsorbent ubiquinol formulation |
JP6146129B2 (en) * | 2013-05-20 | 2017-06-14 | ユーハ味覚糖株式会社 | Method for producing reduced coenzyme Q10-containing gummy candy |
JP5620561B2 (en) * | 2013-10-21 | 2014-11-05 | テクノガード株式会社 | Non-aqueous composition containing drug-containing fat particles and method for producing the same |
ES2942619T3 (en) * | 2014-06-11 | 2023-06-05 | SpecGx LLC | Spray-dried compositions with different dissolution profiles and procedures for their preparation |
GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
KR102555510B1 (en) * | 2016-04-12 | 2023-07-13 | 고려제약주식회사 | Composition for self-emulsifying drug delivery system comprising coenzyme q10 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003007907A1 (en) * | 2001-07-12 | 2003-01-30 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Water-free ubichinon concentrate |
JP2003238396A (en) * | 2002-02-21 | 2003-08-27 | Nisshin Pharma Inc | Coenzyme q10-containing emulsified composition |
JP2003300870A (en) * | 2002-02-08 | 2003-10-21 | Kyowa Hai Foods Kk | Ubiquinone-containing water-soluble composition |
-
2005
- 2005-09-29 JP JP2006537821A patent/JP5147239B2/en active Active
- 2005-09-29 WO PCT/JP2005/018016 patent/WO2006035900A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003007907A1 (en) * | 2001-07-12 | 2003-01-30 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Water-free ubichinon concentrate |
JP2003300870A (en) * | 2002-02-08 | 2003-10-21 | Kyowa Hai Foods Kk | Ubiquinone-containing water-soluble composition |
JP2003238396A (en) * | 2002-02-21 | 2003-08-27 | Nisshin Pharma Inc | Coenzyme q10-containing emulsified composition |
Also Published As
Publication number | Publication date |
---|---|
JP5147239B2 (en) | 2013-02-20 |
WO2006035900A1 (en) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5147239B2 (en) | Coenzyme Q10-containing emulsion composition | |
TWI351925B (en) | Composition comprising coenzyme q10 | |
JP5982086B2 (en) | Novel formulation of fat-soluble active ingredients with high bioavailability | |
JP5343002B2 (en) | Bioactive substance-containing composition | |
JP5150176B2 (en) | Powder composition | |
JP5334492B2 (en) | High concentration astaxanthin extract | |
JP2019135242A (en) | Carotenoid-containing composition | |
EP3056090A1 (en) | Oil/fat composition containing polyunsaturated fatty acid | |
JPWO2006030850A1 (en) | Method for preparing solubilized product of fat-soluble component | |
TW200916090A (en) | Composition comprising coenzyme Q10 | |
JP2011032171A (en) | Skin whitening composition | |
JP2009062330A (en) | Powder composition | |
JP4859006B2 (en) | Stable astaxanthin-cyclodextrin inclusion compound and method for producing the same, and liquid, food and drink, feed, pharmaceuticals and cosmetics containing the inclusion compound | |
JP2008239619A (en) | Peripheral blood circulation ameliorative composition | |
JP2008179619A (en) | Astaxanthin containing composition | |
JP2009114184A (en) | Powder preparation, food composition, cosmetic composition, and pharmaceutical composition | |
JP2014019660A (en) | Active oxygen inhibitor | |
JP2015209398A (en) | High absorption type ubiquinol formulation | |
JPWO2009048120A1 (en) | Astaxanthin-containing water-soluble composition | |
EP1747778B1 (en) | Anti-fatigue composition | |
JP2013245213A (en) | Clathrate of eriobotrya japonica leaf culture extract and cyclodextrin | |
JP5878590B2 (en) | Container drink | |
JP2008174537A (en) | Powdered composition, and food composition, cosmetic composition and pharmaceutical composition containing the same | |
JPWO2012157290A1 (en) | Non-alcoholic steatohepatitis prevention and improvement agent | |
WO2007080787A1 (en) | Coenzyme q10-containing water-soluble compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120210 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5147239 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151207 Year of fee payment: 3 |